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General introduction and outline of this PhD thesis
With exception of lymph nodes, the lungs are the most common site of
metastatic involvement for all invasive cancer types. The most obvious
reason is the filtering of circulating tumour cells by the pulmonary capillairy
bed. The incidence of pulmonary metastases is unknown, and has been
estimated to occur in approximately 50% of patients with non-pulmonary
malignancy.
The most common primary malignancies are breast, colon, kidney, uterus,
prostate and nasopharyngeal carcinomas. Other primary tumour types that
especially metastasise to the lungs are melanoma, germ cell tumour, soft
tissue sarcoma and osteogenic sarcoma. The high incidence of pulmonary
metastases in autopsy studies may overestimate both the true incidence of
initial lung involvement and its clinical significance.
Current treatment of pulmonary metastases consists of surgical resection and
adjuvant chemotherapy. Results from the international database, reported by
Pastorino et al, show a 5-year survival after metastasectomy of almost 70%
for patients with germ cell tumours, 37% for epithelial tumours, 30% for
sarcomas and 20% for melanomas. The mean 5-year survival of pulmonary
metastases is 37% after surgical resection and adjuvant chemotherapy and
0% if not treated.
Isolated lung perfusion (ILuP) is an experimental surgical technique for the
treatment of pulmonary metastases in order to improve the current 5-year
survival of approximately 40% after resection of lung metastases. The main
advantage is that higher lung levels can be obtained without systemic
toxicity which reduces overall toxicity. ILuP as an adjuvant treatment during
surgical resection aims to destroy micrometastases but its use as induction
therapy should be explored as well.
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In this thesis the results are presented of isolated lung perfusion with
gemcitabine for the treatment of pulmonary metastases. This study was set
up in 1999 at the Laboratory of Experimental Surgery at the University of
Antwerp. The primary aim was to find out the efficay of gemcitabine for the
treatment of pulmonary micrometastases from colorectal adenocarcinoma.
Its use in the clinical setting of isolated lung perfusion was studied and
compared to intravenous therapy.
Gemcitabine and melphalan are the main drugs studied in this thesis.
Therefore, their mechanisms of action and their clinical activity are
described at the end of this general introduction.
As an introduction, the role of pneumonectomy for the current treatment of
lung metastases is discussed in chapter 1.
A short review about the experimental work is presented in chapter 2.
Several drugs like melphalan, doxorubicin, cisplatin and TNF-a have been
investigated in this model. Melphalan was the most successful anticancer
drug used in isolated lung perfusion which resulted in a currently ongoing
clinical trial.
In chapter 3, in vitro and in vivo (acute) toxicity and pharmacokinetics of
gemcitabine in isolated lung perfusion are compared to systemic intravenous
treatment using the unique rat model of isolated lung perfusion which was
firstly described by Weksler and modified in our laboratory by Hendriks in
1999.
The disadvantage of ILuP is its invasive nature which limits repetitive
treatment. In preparation of less invasive techniques, chapter 4 contains a
description of a pharmacokinetic study to the first-pass effect of gemcitabine
in a rat model of selective perfusion of the pulmonary artery during blood
flow occlusion without clamping the pulmonary veins.
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In chapter 5, two specific techniques of isolated lung perfusion namely
single-pass perfusion versus reperfusion, were compared using melphalan in
the perfusion circuit. Furthermore, the influence of red blood cells as a
possible carrier of melphalan was evaluated using rabbit red blood cells
which were processed according to a specific protocol.
In chapter 6, long-term toxicity and efficacy of isolated lung perfusion with
gemcitabine are presented. For this study a model of unilaterally induced
pulmonary metastases was used which prevented death of the rats due to
bulky disease on the untreated (right) side. Furthermore, lung fibrosis was
studied in a dose escalating toxicity study whereby isolated lung perfusion
with gemcitabine was compared with intravenous infusion.
Because of their different mechanisms of cytotoxicity, chapter 7 describes
the in vivo efficacy of combinations of gemcitabine, cisplatin and melphalan
for the treatment of pulmonary metastatic colorectal adenocarcinoma in a rat
model of isolated lung perfusion.
Discussion (English) and summary (English and Dutch)
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Gemcitabine
Cellular actions
2’,2’-Difluorodeoxycytidine (dFdC, gemcitabine) is a nucleoside analogue
of deoxycytidine in which two fluorine atoms are incorporated in the
deoxyribofuranosyl ring. dFdC enters the cell by several transport
mechanisms either facilitated or energy-dependent processes. These
mechanisms are currently not fully understood. dFdC is phosphorylated by
deoxycytidine kinase which results in gemcitabine di- (dFdCDP) and
triphosphate (dFdCTP). Studies using radioactive dFdC showed that
dFdCTP was the major cellular metabolite compared to dFdCMP and
dFdCDP [1]. This observation implies that phosphorylation to dFdCMP is
the rate-limiting step in the formation of dFdCTP. After incorporation of
phosphorylated gemcitabine into the DNA, one nucleotide has to be added
until DNA polymerase is not capable any more to proceed (“masked chain
termination”). Because gemcitabine is locked in the DNA, proofreading
exonucleasen are unable to remove gemcitabine nucleotides from this
penultimate position. Polymerization experiments showed that this
phenomenon could be explained by an alteration of the primer configuration
at the 3’-terminus due to the incorporated analogue and therefore a change of
its substrate properties [2]. This effect on polymerase progression is more
severe than just a pause, suggesting that if polymerases can extend beyond
single dFdC residues, incorporation of multiple residues has a seriously
inhibitory effect either on DNA replication or (re)synthesis in response to
damage [3]. Incorporation of gemcitabine is strongly correlated with DNA
synthesis inhibition and loss of viability. Mainly S-phase cells proved to be
sensitive to gemcitabine finally resulting in apoptosis characterized by
generation of internucleosomal DNA fragmentation and apoptotic
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morphology [1]. Two types of DNA fragmentation can be found: (1)
nucleosomal-sized DNA fragmentation which is calcium-dependent and (2)
large-sized double-stranded DNA fragmentation which is not calcium-
dependent [4]. Beside incorporation in the DNA mainly responsible for loss
of viability, gemcitabine is also incorporated into the RNA which is
concentration-dependent as well as the incorporation into the DNA. RNA
synthesis in the CCRF-CEM cell line (human leukemic cell line) is inhibited
after incubation during 24 hours with gemcitabine at 1mM [5,6].
dFdC Elimination is dependent on the cellular concentrations of dFdCTP [1].
Monophasic kinetics was observed at dFdCTP concentrations less than 100
mmol/L while biphasic kinetics with a prolonged terminal elimination phase
was seen at concentrations greater than 100 mmol/L [4]. Metabolic clearance
by deamination activity converts dFdC to dFdU which is predominated in
cells containing relatively low dFdCTP levels. In contrast, dFdC is excreted
from cells having high levels of dFdCTP. So it can be concluded that
deamination is the major elimination route in cells with less than 100 mmol/L
while excretion and dephosphorylation is more important in cells with
dFdCTP levels greater than 100 mmol/L [1]. These results were confirmed
by studies blocking deaminase activity that changed the elimination route
from mono- with a terminal half-life of 3.6 hours to biphasic with a terminal
half-life of 19 hours [4]. Subsequent studies showed direct inhibition of
deaminase activity by dFdCTP and indirectly by depletion of the dCTP pools
that are required for deaminase activity [1].
Compared with ara-C, gemcitabine serves as a better transport substrate, is
phosphorylated more efficiently, eliminated more slowly and contains three
mechanisms of self-potentiating action.
General introduction
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Firstly, gemcitabine diphosphate (dFdCDP) reduces activity of
ribonucleotide reductase which normally produces deoxyribonucleotides and
is time- and concentration-dependent. This results in a reduction of mainly
nuclear dCTP resulting in an increased phosphorylation and therefore
incorporation of gemcitabine nucleotides into the DNA which are
competitive with nuclear dCTP [7]. Furthermore, a reduction of cellular
deoxynucleotide pools necessary for DNA synthesis and repair results in
decreased DNA repair activity.
Secondly as mentioned before, a reduction of nuclear dCTP also results in a
reduced clearance of gemcitabine by deoxycytidine monophosphate
deaminase contributing to the concentration-dependent elimination kinetics.
The combination of slow elimination and efficient phosphorylation are
responsible for accumulation of high concentrations of gemcitabine [8,9].
A third self-potentiating mechanism is a concentration-dependent formation
of active gemcitabine di- and triphosphate which results in an increased ratio
of gemcitabine triphosphate and deoxycytidine triphosphate [9,10].
In conclusion, these metabolic properties and mechanisms of self-
potentiating action enhance effective accumulation and prolonged
intracellular retention that are paralleled the incorporation of gemcitabine
into the DNA and loss of viability. This shows evidence for a mechanistic
relationship between the metabolism of gemcitabine and its biologic actions
[4].
Anti-tumour activity
Clinical activity of intravenous single-agent treatment with gemcitabine was
shown in ovarian, breast, colorectal, breast, pancreas and NSCLC [11,12].
Gemcitabine is extremely well tolerated even in heavily pre-treated patients
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[13]. The combination of its mechanistic and metabolic properties suggests a
possibility of synergistic effects if combined with some other
chemotherapeutics [14]. Response rates in treatment of advanced breast
cancer with gemcitabine vary from 25 to 46% [13]. Combinations of
gemcitabine with several products like doxorubicin, epirubicin and
paclitaxel, cisplatin, paclitaxel, docetaxel, 5-FU and vinorelbine have been
studied [15-21]. The best results have been achieved with gemcitabine
combined with epirubicin and paclitaxel [16].
Furthermore, gemcitabine seems to be a promising radiation sensitizer [22].
Radiosensitization occurs under conditions in which cells demonstrate
concurrent redistribution into S phase and deoxyadenosine triphosphate pool
depletion. Prolonged clinical benefit response and disease stabilization was
achieved in patients with localized, unresectable pancreatic cancer [23].
Melphalan
Mechanism of action
Melphalan is a bifunctional alkylating agent that is actively transported into
cells by the high-affinity L-amino acid transport system. Since this system
also transports the amino acids glutamine and leucine, high concentrations of
either of these aminoacids will reduce the uptake in tumour cells in vitro
(24). A second less effective transport system may contribute to melphalan
uptake next to alanine, serine and cysteine. In addition to aminoacids,
melphalan uptake is also inhibited by tamoxifen, doxorubicin,
aminophylline, chlorpromazine, and indomethacin (25).
Once transported into the cell, cytotoxicity is accomplished by forming
either DNA-interstrand, DNA-intrastrand, or DNA-protein cross-links (26).
Probably, melphalan quickly forms monoadducts, which then only slowly
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convert to cytotoxic DNA-DNA or DNA-protein bonds (27). Similar to other
alkylating agents, melphalan is non-cell cycle phase specific which makes it
active against both resting and rapidly dividing tumour cells (28).
Drugs and compounds that increase the cytotoxicity of melphalan include 1-
deamino-8-D-arginine vasopressin (increases intracellular concentrations),
nicotinamide (inhibition of poly [adenosine diphosphate-ribosel polymerase,
which increases the half-life ), tissue oxygenation, and intracellular
glutathione (GSH) (29-31).
Antitumour effect in clinical trials
The activity of intravenously infused melphalan at doses less than 65 mg/m2
has been reviewed by Sarosy (33). At this dose, melphalan has documented
activity in ovarian cancer, rhabdomyosarcoma, pancreatic carcinoma,
osteogenic sarcoma, and glioma. At doses less than 65 mg/m2, melphalan has
little activity in breast, lung, or colorectal cancer. However, with high dose
melphalan given intravenously an extraordinarily high response rate is seen
in "resistant" solid tumours such as melanoma (34,35) and colorectal
carcinoma (36,37). The observed response rate of 45% after high-dose
melphalan (HDM) and bone marrow transplantation (BMT) in metastatic
colon cancer as reported by Leff is impressively high (36). Unfortunately,
this response is of brief duration. Leff et al noted nine objective responses
among 20 evaluable patients, with a median duration of survival of 198 days.
Spitzer treated 14 patients, previously treated with, and refractory to,
conventional chemotherapy (37). They received melphalan 120 to 180
mg/m2 (total dose) divided as 40-60 mg/m2 iv daily for 3 days with the
modulator misonidazole. The response rate was six of 14 patients (43%) and
all responses were PRs. The median duration of response was 4 months.
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Isolated Limb Perfusion
Melphalan was identified as a potential agent for use in isolated limb
perfusion (ILP) because in vitro studies demonstrated that it was taken up
and retained by melanocytes and it was one of the few alkylating agents
available in the late 1950s when this operation was conceived (40).
The amount of melphalan administered during ILP has varied over time.
Initial series calculated melphalan dose on the basis of body weight with a
maximum tolerated dose of 1.75 mg/kg and a 2.0 mg/kg dose-limiting
regional toxicity (41). However, this calculation does not take into account
the wide variation of body habitus and the distribution of weight among
individuals. Therefore, melphalan dose is now calculated on the basis of
limb volume as proposed by Wieberdink (42, 43). The most widely used
dose based on limb volume is 10mg/L limb volume for the lower extremity
and 13mg/L limb volume for the upper extremity perfusion (44). A phase I
trial of escalating melphalan dose defined 14 mg/L as the MTD, with 16
mg/L or a total dose greater than 150 mg resulting in dose-limiting regional
toxicity (45).
The majority of melphalan leaves the perfusate during the course of a 60-
min treatment, but most of the dose is absorbed by the tissue of the perfused
extremity within the first 30 min. The initial loss with a half-life (T1/2) of
approximately 5-10 min is interpreted as rapid uptake of melphalan by the
tissue. The terminal portion of the curve with a half-life of approximately
35-50 min is interpreted as due to the hydrolysis of melphalan, with a lesser
component of loss due to absorption to the filters and tubing of the perfusion
apparatus. Based on the AUC, the authors suggest that perfusion with
melphalan for longer than 30 to 40 min is unnecessary but further studies are
required (46).
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Two important prospective trials that have evaluated the use of ILP with
melphalan in an adjuvant setting for localized, high-risk melanoma showed a
significant decrease in recurrent disease but no difference in overall survival
rate between treatment groups (47, 48).
A few prospective randomized trials of therapeutic ILP have been reported,
both normothermic (48-49) and hyperthermic (50-52). No trials have
compared ILP with systemic treatment since the response rates of the latter
are too low. Generally, complete responses for therapeutic ILP with
melphalan alone are 40-60%, with an overall response of approximately
80%.
Interest in ILP as a surgical therapy has been renewed since adding highdose
Tumour Necrosis Factor to a melphalan ILP.
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Abstract
Today, pulmonary resection for lung metastases is a widely accepted
treatment if complete resection can be achieved. However, 5-year survival is
only 40%. Many patients develop recurrences, but some reports have
demonstrated that salvage operations can result in a long-term survival. A
resection of a complete lung or a resection of more than a lung is still
controversial since procedure-related morbidity or mortality does not
outweigh the survival benefit. We report on a series of 10 consecutive
patients who underwent a primary pneumonectomy or an operation on the
residual lung after pneumonectomy with curative intent for pulmonary
metastases. 5-Year survival rates for the 10 patients after pneumonectomy
alone or with additional resection was 45 %, which was not significantly
different from those who underwent a more minor resection with a 5-year
survival of 39% (p = 0.40). Since there is currently no alternative proven
therapy for patients with isolated pulmonary metastases, a primary or
completion pneumonectomy may be offered to selected patients as long as
sufficient pulmonary reserve is present, and a complete resection can be
achieved.
Introduction
At present, pulmonary resection for lung metastases is a widely accepted
treatment if complete resection can be achieved. However, 5-year survival
rate is only approximately 40% [1]. Many patients develop recurrences that
are often inoperable due to insufficient pulmonary reserve or location, or the
number of metastases. Intrathoracic recurrences occur in more than 50% of
epithelioma and sarcoma metastasis patients [2,3]. Some reports have
demonstrated that salvage operations can result in long-term survival
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provided that a complete resection of all metastatic disease is accomplished
[4,5]. However, a resection of a complete lung alone or with additional
resection remains controversial since procedure-related morbidity or
mortality does not outweigh survival benefit. Two patients who underwent a
resection beyond pneumonectomy in our institution were reported in 1999
[6]. In this communication, we report on a series of 10 consecutive patients
who underwent a primary pneumonectomy or an operation on the residual
lung after pneumonectomy with curative intent for pulmonary metastases.
Materials and Methods
Over a l0-year period from January 1990 to December 2000, 10 patients
were operated on for recurrent pulmonary metastatic disease resulting in a
pneumonectomy alone or with additional resection in order to achieve a
complete resection. All patients had a complete preoperative work-up to
exclude extrathoracic metastatic disease. These investigations included a
computed tomographic (CT) scan of the thorax, a bone scan, a CT scan of
the abdomen and a PET scan in the last two patients. When the thoracic CT
scan showed enlarged mediastinal lymph nodes, a cervical mediastinoscopy
was performed. There were 7 male and 3 female patients with a mean age of
42 years (range, 17 to 61 years) at the time of the initial operation. These
patients are described in Table 1, and represent 14% (10/73) of all
pulmonary metastasis operations at our Department of Thoracic Surgery
over the same period [3].
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Results
In 3 patients, a primary pneumonectomy was performed, meaning that
removal of an entire lung was necessary at the first metastasectomy. The first
patient developed lung metastases 180 months after resection of a
leiomyosarcoma in the back. After the initial right pneumonectomy, he
underwent an additional wedge resection on the left side due to tumour
recurrence. Three nodules were removed, and he survived for 50 months
after the initial pulmonary resection. He finally died of recurrent disease
outside the lung (Table 1, patient no. 2).
The second patient developed metastatic disease 38 months after a sigmoid
resection due to a colon adenocarcinoma. Five nodules were removed in a
left pneumonectomy operation, and the patient died because of a cerebral
primary tumour 66 months after the operation (Table 1, patient no. 7).
The third patient had a right pneumonectomy for lung metastases 12 months
after resection of a leiomyosarcoma in the pubic region. A total of 2 nodules
were resected; the patient survived for only 8 months, dying of recurrent
disease in this left lung (Table 1, patient no. 8).
All other patients (n = 7) had repeated salvage surgery for lung metastases
resulting in a completion pneumonectomy alone or with additional resection.
Indications were one teratocarcinoma in two patients and one liposarcoma,
leiomyosarcoma, adenocystic carcinoma, osteosarcoma and chondrosarcoma
in one each of the others. The number of procedures ranged from 2 to 3
resections for a total of 5 to 11 lesions. The mean diameter of the pulmonary
nodule was 66 mm (range, 25 to 140 mm). The mean time interval between
the initial operation of the primary tumour and resection of the lung
metastases was 37 months (range, 0 to 55 months).
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No. Age Gender Histology Location ofPrimary
Number of
procedures
Type of
PneumonectomySide Alive
Follow-up in
months
after 1" Ms.
1 57 male Liposarcoma Femur R 3 Completion L yes 30
2 22 male Leiomyosarcoma Back 2 Primary R no 50
3 23 male Teratocarcinoma Testis L 2 Completion R yes 193
4 61 male Leiomyosarcoma Pubic region 3 Completion R no 48
5 53 female Adenocystic ca Tongue 2 Completion R no 41
6 43 male Teratocarcinoma Testis R 2 Completion R no 47
7 57 male Colon adenoca Sigmoid 1 Primary L no 66
8 72 female Leiomyosarcoma Back 1 Primary R no 8
9 17 male Osteosarcoma Knee L 3 Completion L yes 107
10 19 female Chondrosarcoma Femur L 3 Completion R yes 101
Table 1. Patient characteristics
Four patients are still alive 30, 101, 107 and 193 months after the first
pulmonary metastasectomy, respectively (Table 1).There was lymph node
involvement in three cases. These included stations 7 (subcarinal) and 9
(inferior pulmonary ligament), stations 11 (interlobar) and 7, and station 5
(aortopulmonary window respectively, according to the Naruke lymph node
map [7]. These 3 patients with lymph node involvement survived for 23, 41
and 78 months.
The postoperative course was uneventful in 9 further patients. One patient
(Table 1, no. 4) died on the 11th postoperative day of aspiration pneumonia
in the left lung after a right completion pneumonectomy for metastases of a
leiomyosarcoma in the pubic region resected 7 years before! He had
undergone three metastasectomies for a total of 11 metastatic nodules during
these 7 years. The survival analysis is depicted in Fig. 1. The 5-year survival
rate for the 10 patients who underwent pneumonectomy alone or with
additional resection was 45 %, not significantly different from those patients
who underwent a lesser resection with a 5-year survival of 39 % (p = 0.40).
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Fig 1.
Survival of patients
with lung
metastases
undergoing a
pneumonectomy or
a lesser resection
In addition, the survival curve starting from the date of the pneumonectomy
is depicted in Fig. 2 (5-year survival of 45 %).
Fig 2.
Survival of patients with
lung metastases starting
from the data of the
pneumonectomy
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Author No. of patients
with CR
MST in months Operative mortality in % Survival at 5 years in
%
McGovern 1988 [8]
Putnam 1993 [9]
AI-Kattan 1995 [10]
Spaggiari 1998 [11]
Koong 1999 [12]
Bernard 2001 [13]
Present Series
19
19
5
42
112 PP and 31 CP
32
10
20
27
NS
6.5 (1-144)
17 for PP and 29
for CP
NS
50
0
10.5
0
4.8
4 for PP and 3 for CP
9.4
10 (single case)
40.8
21
NS (3 alive> 5 years) 17
17
20 for PP and 30 for CP
NS
45
Table 2. Literature review
Discussion
Surgical resection is a widely accepted treatment for pulmonary metastases
in certain solid tumours. Many patients develop recurrent disease after
metastasectomy, which is reflected by the low 10-year survival rate of 26%
[2]. The optimal therapy is still unknown, but systemic chemotherapy does
not result in a major survival advantage
Regarding the operation, the sole criterion is that only complete resection
can result in long-term survival [2]. Both the primary role and extent of
surgery for recurrent lung metastases remain controversial. The reported
operative mortality rates from various centres ranges from 0% to 10.5% [8-
13] (Table 2). Several reports favour salvage surgery, having demonstrated
long-term survival after repeated resections for recurrent pulmonary
metastases from soft-tissue sarcoma [4,5]. This is probably due to the fact
that the majority of metastatic sarcoma patients have "lung-only metastases"
[14], while more than 50 % of all relapses from sarcoma are intrathoracic
[2,3]. However, this long-term survival was also shown in a heterogeneous
group of other tumours [8,15-17]. Five-year survival rates of around 20% are
seen (range, 9 to 41 %), and are lower for primary pneumonectomy than for
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completion pneumonectomy [8-13] (Table 2). This long-term survival may
be lower than the 5-year survival rate of 36% for all pulmonary
metastasectomy cases [2], but it still remains superior to no resection at all.
In conclusion, since no alternative proven therapy is available for patients
with isolated pulmonary metastases, a primary or completion
pneumonectomy may be offered to select patients as long as sufficient
pulmonary reserve is present and complete resection can be achieved. Since
recurrent disease within the lung is probably due to micrometastatic disease
present at the time of initial operation, isolated lung perfusion with high-
dose chemotherapy as an adjunct to surgical resection may be a promising
therapy. Excellent results have been obtained in animal models, but the
results of clinical trials to determine whether there is a real survival benefit
are still pending in patients with pulmonary metastatic disease [18-20].
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Abstract
Surgical resection of lung metastases is a widely accepted procedure but
long-term results are disappointing with a 5-year survival rate of
approximately 40%. Pulmonary metastasectomy is only indicated when
complete resection can be achieved. A better survival is reported in patients
with a single metastasis or a disease-free survival of more than 3 years.
Intravenous chemotherapy has no major impact on survival because high-
dose therapy is limited by systemic side effects. Isolated lung perfusion has
the advantage of both selectively delivering an agent into the lung while
diverting the venous effluent. This allows the drug to be given in a
significantly higher dose compared to intravenous therapy, while drug levels
in critical organs are kept low enough to avoid significant morbidity.
Isolated lung perfusion has proven to be effective for the treatment of lung
metastases in animal models while the procedure is technically safe in
humans. However, the real clinical value and survival benefit remain to be
determined in ongoing clinical trials.
The aim of this paper was to update the literature on isolated lung perfusion
for the treatment of lung metastases. Furthermore, some proposals are made
in order to improve the ultimate prognosis of these patients.
Introduction
Cancer remains the second cause of death with almost 550 000 deaths
expected for the USA in 2002 [1]. Currently, 40-50% of all cases of
malignancy are cured [2]. The non-cured group mostly suffers from
metastases. At the moment of diagnosis of the primary tumour, metastases,
which are too small to be detected, so called micrometastases, may already
be present. Furthermore, widespread metastatic disease may be symptomless
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at an early stage.
With exception of the lymph nodes, the lungs are the most common site of
metastatic involvement for all invasive cancer types. The most obvious
reason is the filtering of circulating tumour cells by the pulmonary capillary
bed. The precise incidence of pulmonary metastases is unknown, but has
been estimated to occur in up to 50% of patients with non-pulmonary
malignancy [2].
The cumulative incidence and prevalence of pulmonary metastases vary
widely according to tumour type and observed time interval between the
occurrence of the primary cancer and its metastases. Some tumour types
preferentially metastasise to the lungs, such as sarcomas, germ cell tumours
and some paediatric malignancies. Gastrointestinal tumours will first
metastasise to the liver and from there to the lungs. The high incidence of
pulmonary metastases in autopsy studies may overestimate both the true
incidence of initial lung involvement and its clinical significance.
Current treatment of pulmonary metastases consists of surgical resection and
adjuvant chemotherapy. Results from the international database, reported by
Pastorino et al., showed a 5-year survival after metastasectomy of almost
70% for patients with germ cell tumours, 37% for epithelial tumours, 30%
for sarcomas and 20% for melanomas [3]. Furthermore, this study
investigated prognostic factors for lung metastasectomy. Radiological
staging is unreliable with an accuracy in patients undergoing unilateral
thoracotomy of 75%, while accuracy in patients undergoing median
sternotomy or bilateral thoracotomy was only 37%. Thorough, intraoperative
staging is therefore required to identify and resect all metastases. Pastorino
et al. demonstrated the prognostic value of the number of metastases with a
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Group Prognostic factors Median survival
Group 1
Resectable, no risk factor (DFI > 36 months and
single metastasis)
61 months
Group 2
Resectable, 1 risk factor (DFI < 36 months or
multiple metastases)
34 months
Group 3
Resectable, 1 risk factor (DFI < 36 months and
multiple metastasis)
24 months
Group 4 Unresectable 14 months
Table 1. Prognostic groups in patients with lung metastases based on three
prognostic parameters: respectability, DFI and number of metastases [3].
5-year survival rate of 43% in case of a single metastasis dropping to 27% in
case of 4 or more metastases. They also showed that the proportion of
patients that underwent a second metastasectomy was in accordance with the
probability of intrathoracic relapse. The 5-year survival of patients who had
a second metastasectomy was remarkably good (44% versus 34% for
patients having a single operation). Based on three parameters of prognostic
significance (resectability, disease-free interval and number of metastases)
four prognostic groups could be identified (table 1) taking all parameters into
account [3]. In 1999 we published a mini-review on isolated lung perfusion
[4]. In this manuscript we updated the results with isolated lung perfusion,
both experimentally and clinically.
Isolated Lung Perfusion
Experimental research in animal models
In selected cases, pulmonary metastasectomy is an effective treatment for
patients with isolated lung metastases. However, 5-year survival rate for all
tumour types is only 30-40% [3]. Intravenous therapy is dose-limited due to
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systemic side effects. So novel techniques should be developed in order to
improve prognosis. It was Creech in 1959 who first reported a model of
isolated lung perfusion to achieve high local drug levels without apparent
systemic toxicity [5]. He perfused both lungs simultaneously with divided
circuits for systemic and pulmonary circulations. In 1960, Pierpont and
Blades and in 1961, Jacobs described a method of isolated in vivo perfusion
of a single lung. As shown by radioisotope studies no leakage of the drug
outside the pulmonary circulation was present [6,7]. Johnston put the base
for further clinical and experimental studies by demonstrating isolated
single-lung perfusion to be a safe and reproducible technique [8-10].
Doxorubicin lung levels were determined in a dog model without control of
the bronchial arterial blood flow and with apparently no systemic toxicity.
This can be explained by a recent study which shows that a significant
portion of both pulmonary and metastatic tumour vasculature is fed by the
pulmonary arterial circulation [11]. However, bronchial artery infusion is the
desired route in primary bronchogenic carcinoma, which is mainly fed by the
bronchial circulation [12].
Later on, Weksler described a rat model of unilateral isolated lung perfusion,
which was later modified by Wang and by Hendriks [13-15]. Briefly, in this
model a left thoracotomy is performed after inducing anaesthesia.
Subsequently, the rib retractor and lung are placed anteriorly and the hilum
is dissected free from the posterior side. After clamping the pulmonary
artery and vein with curved microclips, an introductory needle is placed
through the chest wall. A perfusion catheter is introduced into the chest
through the needle and secured by a 4/0 silk tie after insertion into the
pulmonary artery. Perfusate is delivered through this catheter. In addition, a
pulmonary venotomy is performed and two venous catheters are placed into
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the superior and inferior pulmonary vein to collect the venous effluent
(figure 1). Nawata et al. recently described a rat model of bilateral isolated
lung perfusion performing a left and right thoracotomy sequential with a
time interval of one week minimally [16]. Several drugs have already been
tested in the unilateral model and some of them proved to be very effective.
These are summarized in table 2.
Initially doxorubicin was studied and Baciewicz et al. did not observe any
toxicity using this drug [17]. Weksler reported a rat study in which
micrometastases were induced in the left lung at day 0. After seven days, rats
were treated with left isolated lung perfusion using doxorubicin. Animals
were sacrificed after three weeks and eradication of metastases was observed
in the left lungs while the right lungs had massive tumour replacement [18].
Significantly longer survival and even complete remission after six weeks
was observed by Abolhoda after isolated lung perfusion with doxorubicin in
a rodent model of metastatic pulmonary sarcoma [19].
Based on the antitumour effect of TNF-a, Weksler reported that a single
treatment of isolated lung perfusion with TNF-a can be done safely and is
effective in decreasing the number of sarcoma lung metastases using a rat
model [20,21]. Although combining melphalan with TNF-a resulted in
excellent synergistic effects in isolated limb perfusion for the treatment of
melanoma, synergistic effects using a single treatment with TNF-a in
combination with melphalan could not been confirmed by Hendriks in a
model of adenocarcinoma metastases [22].
However, a significant reduction in number of lung nodules was observed
after single treatment with melphalan in a rat model of metastatic sarcoma as
well as a reduction in number of nodules and a significantly longer survival
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Figure 1. Experimental setting of a rat model of isolated lung perfusion.
“A” shows a reperfusion circuit in which the perfusate is circulating
between the perfusate reservoir and the lung.
“B” shows a single-pass perfusion system in which the perfusate is sucked
towards a reservoir after passing the lung once.
in a rat model of metastatic adenocarcinoma [22-24]. Pogrebniak et al.
applied TNF-a in a swine model of isolated lung perfusion. They concluded
that the use of TNF-a is feasible when intraoperative systemic serum levels
are monitored to ensure adequate pulmonary isolation [25].
Ng reported significantly less pulmonary nodules after isolated lung
perfusion with a fluorinated pyrimidine (FUDR) using a rat model of
pulmonary metastatic colorectal adenocarcinoma [26]. In vitro assays
described by Schrump showed enhanced paclitaxel-mediated cytotoxicity of
5 to 100 times in cultured cancer cell lines under hyperthermic conditions
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compared to normothermic conditions. However, no paclitaxel toxicity was
observed in cultured normal human bronchial epithelial cells after exposure
under normothermic or hyperthermic conditions [27].
Cisplatin proved to be very effective in treatment of pulmonary metastatic
sarcoma with enhanced antitumour effect in combination with digitonin [28].
Isolated lung perfusion can be performed antegradely by way of the
pulmonary artery or retrogradely by way of the pulmonary veins, which
results in drug distribution to the areas perfused by the pulmonary and
bronchial circulation as well. The feasibility and toxicity of retrograde
perfusion with doxorubicin was studied in a rat model and compared to
antegrade perfusion [29]. However, no significant difference was measured
between retrograde and antegrade isolated left lung perfusion regarding the
uptake of doxorubicin in lung tissue [29]. No significant differences in
weight of the rats were observed during the follow-up period. Furthermore,
feasibility of hyperthermic retrograde isolated lung perfusion was
demonstrated with paclitaxel in a sheep model [28].
Rickaby et al. investigated the influence of hyperthermia in a dog model of
isolated lung perfusion. Temperatures up to 44.4º Celsius did not have any
detectable influence on the measured variables [30].
Recent studies in our laboratory showed cell kill of adenocarcinoma cells
due to gemcitabine to be time and concentration-dependent [31]. This
finding is the basic argument for treatment of lung metastases with isolated
lung perfusion to deliver high local drug levels without severe systemic
toxicity. Isolated lung perfusion resulted in significantly higher gemcitabine
lung levels compared to systemic serum levels after isolated lung perfusion
using the maximum tolerated dose of 320 mg/kg gemcitabine in a rat model
of metastatic pulmonary adenocarcinoma [31]. Gemcitabine also resulted in
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significantly longer survival in this rat model [32]. In contrast to melphalan,
which is dose-dependent, gemcitabine proved not to be dose-dependent
within the studied flow range [33-35]. Further research is necessary to find
out gemcitabine to be concentration- and/or flow-dependent. If a drug is
concentration-dependent recalculation of the amount of the drug to be
administered to other species is less complicated when a single bolus
perfusion is applied in which the concentration of the drug delivered is
stable.
Author Product Model Species Dose Time
Efficacy
Decrease number
nodules (p)   Survival
(p)
Abolhoda [19] Doxorubicin sarcoma Rodent 6.4 mg/kg 15 min <0.0001***
Weksler [18] Doxorubicin sarcoma Rat 6.4 mg/kg 10 min <0.001
Weksler [20] TNF-a sarcoma Rat 1.7 mg/kg 10 min 0.01**
Hendriks [22] TNF-a + melphalan carcinoma Rat 2 mg/kg + 1.2 mg/kg 25 min <0.0001*
Hendriks [22] TNF-a carcinoma Rat 300 mg 25 min NS**
Nawata [24] Melphalan sarcoma Rat 8 mg/kg 20 min 0.01*
Hendriks [23] Melphalan carcinoma Rat 2 mg/kg 25 min <0.0001**    0.0002***
Ng [26] FUDR carcinoma Rat 1400 mg/kg 20 min <0.05*
Van Putte [32] Gemcitabine carcinoma Rat 320 mg/kg 25 min                          0.02***
Tanaka [28] Cisplatin sarcoma Rat 2 mg/kg 10 min NS***
Tanaka [28] Cisplatin + digitonin sarcoma Rat 2 mg/kg + 1.6 mmol/kg 10 min <0.0001***
Table 2. Animal studies investigating efficacy of isolated lung perfusion for
the treatment of pulmonary metastases
* p-value compared to iv treatment
** p-value compared to the untreated right lung
*** p-value compared to controls
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Less invasive models for the treatment of pulmonary metastases
In preparation of less invasive methods of selective perfusion of the lung, we
investigated the first-pass effect of gemcitabine during low flow pulmonary
artery perfusion (0.2 ml/min) using blood flow occlusion of the pulmonary
artery without control of the pulmonary veins. Low flow pulmonary artery
perfusion with 16 mg (64 mg/kg) of gemcitabine resulted in significantly
lower systemic gemcitabine serum levels and significantly higher lung levels
compared to intravenous infusion of 40 mg (160 mg/kg) of gemcitabine [34].
This emphasizes the feasibility of chemotherapy infusion of gemcitabine by
sequential selective catheterisation of the pulmonary artery using blood flow
occlusion without control of the pulmonary veins.
Schneider reported a rat model of chemoembolization of solitary metastasis
in the lung [36]. Efficacy was comparable to isolated lung perfusion but
chemoembolization seems advantageous because it only requires injection of
degradable starch microspheres (DSM) together with a cytotoxic drug into
the pulmonary artery by an endovascular catheter.
Ex vivo model of isolated lung perfusion
Beside this extensive research in the rat model, Linder described an ex-vivo
model in which human lungs can be perfused by isolated lung perfusion in
order to study physiology, pharmacokinetics and different surgical
procedures [37]. The lung specimens used are obtained after resection in
cases of bronchial carcinoma. Reproducibility of the experiments was
evaluated by the net weight gain, wet-to-dry ratio, angiography of the
pulmonary artery, pulmonary vascular resistance, fluorescence of the lung
surface and alveolar gas diffusion into the perfusate.
The uptake of doxorubicin was investigated in this model and compared with
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the uptake of a non-toxic glucuronide prodrug (HMR 1826) from which
doxorubicin is released by the action of beta-glucuronidase present in high
levels in many tumours. Seven-fold higher lung levels of doxorubicin were
measured in the lung cancer cells after perfusion with the non-toxic prodrug
compared to perfusion with doxorubicin itself [38]. Another study showed
ten-times higher levels of doxorubicin in the lung tissue than in the tumour
tissue while perfusion with the prodrug of doxorubicin resulted in equal
levels in the tumour and lung tissue as well [39]. Furthermore, ex vivo study
investigating the uptake of gemcitabine and melphalan into the human has
started as a result of the successful application of both drugs in the rat model
[22,32,35].
Human studies of isolated lung perfusion (table 3)
Although no animal models or ex vivo models can exactly define human
tolerance to any drug, four clinical phase I trials have been performed using
tumour necrosis factor, platinum and doxorubicin respectively [40-43].
Except for one study by Ratto et al., all patients had inoperable pulmonary
metastatic disease and perfusions were performed in the antegrade way.
However, in contrast to all rat studies using the single-pass perfusion
technique, a reperfusion circuit was applied in these four studies. Because of
the continuous uptake of the drug into the lung, the concentration in the
circuit is not constant while the concentration delivered is stable in a single-
pass perfusion system. However, previous animal studies in our laboratory
did not show significant differences in final lung and tissue melphalan levels
between single-pass perfusion and reperfusion [35].
All human studies concluded that the human model of isolated lung
perfusion is feasible and results in higher lung and tumour levels while
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minimizing systemic toxicity. Although efficacy was not the primary aim of
these studies and no study was conducted as a phase II trial, responses were
disappointingly low. Based on results from animal models and on the
maximally tolerated dose in isolated limb perfusion, specific doses were
determined. However, large variations in final lung and effluent levels were
measured. Therefore, effective drug levels might probably not be reached in
most of the patients with these agents. As noted before, melphalan is one of
the most successful drugs tested in sarcoma and adenocarcinoma animal
models. Currently, a phase I trial is ongoing in our hospital in cooperation
with the St. Antonius hospital (Nieuwegein, the Netherlands). Increasing
doses of melphalan are administered using isolated lung perfusion in patients
undergoing resection of lung metastases, which are melphalan sensitive.
Until February 2003, 11 patients have been treated in this trial without major
morbidity or mortality
Table 3. Phase I trials on isolated lung perfusion for the treatment of
pulmonary metastases (NA: not available)
Author Product Population n Dose Time Flow
Temper
ature of
the lung
Lung
levels
Toxicity
Burt (41) doxorubicin Unresectable 8 40-80
mg/m2
20 min 300-500
mL/min
37°C 1.3-57.3
mg/g
Substantial lung injury
above 40 mg/m 2
Pass (40) TNF-a Unresectable 16 0.3-6 mg 90 min Pressure-
controlled
38-
39.5°C
NA Only one patient had
evidence of systemic
toxicity
Ratto (42) platinum Resectable 6 200
mg/m2
60 min 200-280
mL/min
37-
37.5°C
NA No severe systemic and
pulmonary toxicity
Putnam (43) doxorubicin Unresectable 16 60-75
mg/m2
30 min NA 37°C 74-2750
mg/g
Operative mortality 18.8 %
Early morbidity 23 %
Ongoing
(Antwerp +
Nieuwegein)
melphalan Resectable >20 15-60
mg
30 min 1000
mL/min
37 and
42°C
NA No systemic and pulmonary
toxicity up to 60mg
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Abstract
Background: Toxicity and pharmacokinetics of gemcitabine (GCB) were
evaluated in a rat model of ILuP and compared to intravenous (iv) infusion.
Materials and methods: CC531S adenocarcinoma cells were incubated in
vitro for 24 hours with GCB. Cell survival was determined 4 days after GCB
treatment with the sulphorhodamine B test. In a first in vivo experiment,
Wag/Rij rats underwent left ILuP with 20mg/kg (n=3), 40mg/kg (n=6),
80mg/kg (n=6), 160mg/kg (n=6), 320mg/kg (n=6) of GCB and a control
group (n=6) with buffered starch. After 3 weeks, right pneumonectomy was
performed. Furthermore, survival was determined for rats treated with iv
infusion of 40mg/kg (n=10), 80mg/kg (n=10), 160mg/kg (n=10), 320mg/kg
(n=6) of GCB and a control group (n=6) with saline (0.9% NaCl). In a second
experiment lung and serum GCB levels were determined for rats treated with
iv infusion (160mg/kg, n=6) and rats which had ILuP (160mg/kg, n=6; 320
mg/kg, n=6).
Results: Incubation of the CC531S adenocarcinoma cells with GCB led to a
50% decrease (p<0.05) in the number of cells compared to controls at a dose
of 23.6 nanoM. After 90 days, the mortality for rats treated with 320mg/kg iv
GCB was 100% compared to 17% after ILuP for the same dose. ILuP with
160mg/kg and 320mg/kg resulted in significantly higher lung levels of GCB
compared to iv therapy without any systemic leakage.
Conclusions: GCB ILuP is well tolerated to a maximum dose of 320 mg/kg
and results in significantly higher GCB lung levels with undetectable serum
levels compared to iv treatment.
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Introduction
Colorectal adenocarcinoma remains a serious health problem with 55 000
deaths in 1996 in the United States, and it accounts for a significant number
of isolated lung metastases [1].
Current treatment after isolated pulmonary metastases consists of surgical
resection and systemic chemotherapy. Five-year survival of resection is only
30% to 40% [2,3] and many patients become inoperable due to local
recurrences [4]. Systemic chemotherapy is dose- limited because of high
systemic toxicity and severe side effects. In order to prevent side effects and
to obtain higher local concentrations, Wang et al. developed the technique of
isolated lung perfusion (ILuP) as a new approach for treatment of pulmonary
metastases [5]. Several chemotherapeutics against colorectal adenocarcinoma
have already been tested. Ng et al. reported a significant reduction of the
number of pulmonary nodules in animals treated with ILuP high-dose FUDR
compared to intravenously (iv) treated animals [6]. Hendriks et al. observed a
significant reduction of pulmonary nodules with melphalan and a partial
response to TNF [7]. They also found a significantly longer survival of rats
treated with melphalan and two rats even had tumour-free lungs at sacrifice
[8]. Some recent studies show gemcitabine (GCB) to be active in colorectal
cancer [9,10]. This study was designed to determine sensitivity of CC531S
adenocarcinoma to GCB and to evaluate toxicity and pharmacokinetics of
GCB in a rat model of ILuP compared to iv infusion.
Material and methods
Cell line
In this study CC531S adenocarcinoma cell line was used to determine the
sensitivity for the cytotoxic effect of GCB.
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CC531S was cultured in RPMI-1640 medium, supplemented with 10% fetal
calf serum (Life Technologies, Merelbeke, Belgium). Cultures were
maintained in exponential growth in a humidified atmosphere at 37°C under
5% CO2/95% air.
Cell survival after treatment with gemcitabine
Cells were harvested from exponential phase cultures by trypsinisation,
counted and plated in 48-wells plates. In order to assure exponential growth
during the experiments seeding density was 1000 cells per well. Following
plating and a 24-hour recovery period, cells were treated with GCB (0-200
nM) dissolved in phosphate buffered saline (PBS) during 24 hours. PBS was
added to control cells. Each concentration was tested in sextuple within the
same experiment. After 24-hour incubation with GCB, cells were washed
with drug free medium. After four days, survival was determined by the
sulphorhodamine B (SRB) assay.
The SRB assay was performed according to the method of Skehan and
Papazisis with minor modifications. Culture medium was aspirated prior to
fixation of the cells by addition of 200 mL 10% cold trichloroactic acid. After
1 hr incubation at 4°C, cells were washed 5 times with deionized water. Then
the cells were stained with 200 mL 0.1% SRB (ICN, Asse, Belgium)
dissolved in 1% acetic acid for at least 15 minutes and subsequently washed
4 times with 1% acetic acid to remove unbound stain. The plates were left to
dry at room temperature and bound protein stain was solubilized with 200 mL
10 mM unbuffered TRIS base (tris(hydroxymethyl)aminomethane) and
transferred to 96 wells plates for reading the optical density at 540 nm
(Biorad 550 microplate reader, Nazareth, Belgium).
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The survival rates (%) were calculated by: mean OD (optical density) of
treated cells / mean OD of control cells x 100. The dose response curves were
fitted to the sigmoid inhibition model: E(survival)=1-(Cg / Cg+IC50g)
whereby C is the concentration of the drug and g is a constant, using
Winnonlin (Pharsight, USA) to calculate IC50 values, i.e. the concentration
GCB causing 50% growth inhibition.
Animals
Male inbred Wag-Rij strain rats (weight, approximately 250g), obtained from
Harlan-CPB (Zeist, The Netherlands), were used for all experiments.
Animals were treated in accordance with the Animal Welfare Act and the
“Guide for the Care and Use of Laboratory Animals” (NIH Publication 86-
23, revised 1985). The rats were transported in sterile conditions, housed in
suspended mesh wired cages under standard laboratory conditions and ad
libitum fed a standard pellet diet (standard rat chow, Hope Farms, Woerden,
The Netherlands). The experimental protocols were approved by the
Institutional Animal Care Use Committee, University of Antwerp.
Left Isolated Lung Perfusion
Isolated left lung single-pass perfusion was performed according to the
technique described by Wang et al. [5]. This was modified in our laboratory
and full details have been reported previously [13]. Briefly, rats were
anaesthetized with isoflurane in a mixture of nitrous oxide (NO2) and oxygen
(O2). Isoflurane was administered in a concentration of 4% and the NO2:O2
ratio was 3:1. After 5 minutes, rats were intubated with a 16-gauge Insyte-W
catheter by translaryngeal illumination and afterwards ventilated with a
volume-controlled ventilator (Harvard Rodent Ventilator, South Natick, MA)
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[13]. Once connected to the ventilator, the NO2:O2 ratio was 1:1 (0.5 L/min)
and the rate of ventilation was 75 strokes/min with a tidal volume of 10
mL/kg. Subsequently, the left chest was shaved and prepared with a 70%
alcohol solution, and a left thoracotomy between the third and fourth
intercostal space was performed. After placing a rib retractor, the left lung
was luxated anteriorly and the hilum was dissected free. The pulmonary
artery and vein were clamped with curved microclips. A PE-10 perfusion
catheter (Becton Dickinson, Bornem, Belgium) was introduced into the chest
through a 16-G Angiocath, which was placed through the chest wall. The PE-
10 catheter was inserted into the pulmonary artery and fixed with a 4/0 silk
tie. Perfusate was delivered through this catheter. The effluent was collected
at the venous side by a catheter in proximity of the venotomy (figure 1).
Figure 1.
Experimental setting
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For the pharmacokinetic studies, two catheters (PE-90) were placed in the
superior and inferior pulmonary vein in order to collect the effluent [14].
In all experiments, rats were perfused during 25 minutes followed by a 5-
minute washout with buffered starch at a rate of 0.5 mL/min. In addition,
blood samples were taken out of the left ventricle and subsequently
centrifuged for 20 minutes and frozen in liquid N2 for later analysis.
GCB (Gemcitabine, Eli Lilly Benelux) solutions were prepared by
reconstituting lyophilized powder in the supplied diluent and performing
appropriate dilutions with buffered hydroxy-ethyl starch (Haes Steril, BHE).
GCB in lung and tumour tissue was measured by gas chromatography-mass
spectrometry according to the method described by De Boeck et al. [15].
Statistical analysis
MN levels were analyzed by Student´s t-test. Significance was defined as
p<0.05.
Experiment 1: In vitro toxicity of gemcitabine in CC531S
adenocarcinoma
CC531S cells were treated with different concentrations of GCB during 24
hours. PBS was added to control cells. Each concentration was tested in
sextuple within the same experiment. After 24-hour incubation with GCB,
cells were washed with drug free medium. After four days, survival was
measured by the sulphorhodamine B (SRB) assay. This experiment was
performed three times.
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Experiment 2: In vivo toxicity of gemcitabine in rats
Seventy-five rats were randomized into eleven groups. Groups 1 to 5 had left
ILuP with 20 mg/kg (n=3), 40 mg/kg (n=6), 80 mg/kg (n=6), 160 mg/kg
(n=6) and 320 mg/kg (n=6) of GCB respectively. Group 6 (n=6) had left
ILuP with buffered starch. Rats were perfused during 25 minutes followed by
a 5-minute washout. After three weeks a right pneumonectomy was
performed. Groups 7 to 10 were infused iv with 40 mg/kg (n=10), 80 mg/kg
(n=10), 160 mg/kg (n=10) and 320 mg/kg (n=6) of GCB respectively. Group
11 (n=6) was infused intravenously with saline (0.9 % NaCl). All animals
were sacrificed after 90 days. Weight of the animals was followed during the
whole study period.
Experiment 3: Pharmacokinetics of gemcitabine
Eighteen rats were randomized into three groups (n=6, each). Group 1and 2
had left ILuP with 160 mg/kg and 320 mg/kg of GCB respectively. Rats were
perfused during 25 minutes followed by a 5-minute washout. Effluent was
collected every three minutes during perfusion and every two minutes during
washout and subsequently frozen in liquid N2 for later analysis. After
washout, a blood sample was taken which was frozen after centrifugation
during 20 minutes. Subsequently, the left lung was removed and frozen in
liquid N2 for later analysis. Group 3 was infused iv with 160 mg/kg of GCB.
After 30 minutes the left lung was removed and frozen in liquid N2. Also a
blood sample was taken and after 20-minute centrifugation frozen in liquid
N2.
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Procedure related survival was 100% for all protocols.
Experiment 1: In vitro toxicity of gemcitabine in CC531S adenocarcinoma
The dose response curve of CC531S cells after treatment with GCB (0-200
nM) during 24 hours is shown in figure 2. The IC50 is 23.6 ± 1.1 nM.
Figure 2.
Dose response curve of
CC531S cells after treatment
with gemcitabine
Experiment 2: In vivo toxicity of gemcitabine in rats
Survival rate before right contralateral pneumonectomy was 100% in group 1
to 4 and in the control group and 83% in group 5. One rat in group 1 (ILuP
20 mg/kg) died eight days after right contralateral pneumonectomy and one
rat in group 4 (ILuP 160 mg/kg) died immediately after right
pneumonectomy (table 1). There was no difference in mean weight of the
different ILuP groups before pneumonectomy. However, a significant
difference (p=0.03) was found in mean weight between ILuP 20 mg/kg and
ILuP 80 mg/kg after pneumonectomy (figure 3). A significant difference
(p<0.0001) was found in mean weight between iv 40 mg/kg and iv 320
mg/kg (figure 4). Survival rate was 100% in group 7 (iv 40 mg/kg) and the
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control group (saline), 70% in group 8 (iv 80 mg/kg), 80% in group 8 (iv 160
mg/kg) and 0% in group 10 (iv 320 mg/kg) (figure 5).
Table 1. Survival (%) ILuP groups
Figure 3.
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Figure 4.
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group postoperatively postpneumonectomy after 90 days
ILuP control
ILuP 20 mg/kg
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ILuP 80 mg/kg
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100%
100%
100%
100%
100%
83%
100%
67%
100%
100%
83%
83%
100%
67%
100%
100%
83%
83%
mean weight ILuP groups
0
0,5
1
1,5
2
da
y0
da
y3
da
y6
da
y9
da
y1
2
da
y1
5
da
y1
8
da
y2
1
da
y2
4
da
y2
7
da
y3
0
da
y3
3
w
ee
k6
w
ee
k9
w
ee
k1
2
t ime
m
ea
n 
re
la
tiv
e 
w
ei
gh
t
mean ilup20
mean ilup80
mean ilup320
ILuP
pneumonectomy
Chapter 3
55
survival iv groups 
0
20
40
60
80
100
120
da
y0
day
4
day
8
day
12
day
16
day
20
day
24
day
28
we
ek8
we
ek1
2
time
re
la
tiv
e 
su
rv
iv
al
 (
%
)
iv40
iv80
iv160
iv320
Figure 5.
Survival iv groups
Experiment 3: Pharmacokinetics of gemcitabine
Left ILuP with 160 and 320 mg/kg of GCB resulted in significantly higher
left lung GCB levels compared to rats treated with iv 160 mg/kg of GCB. No
GCB was detected in systemic circulation in the ILuP groups (table 2).
Figure 6 and 7 show GCB effluent levels in function of perfusion time. A
plateau was reached after seven minutes.
lung levels
levels (mg/g)
p serum
(mg/mL)
ILuP 160 mg/kg
ILuP 320 mg/kg
iv 160 mg/kg
1.5 ± 1.6
2.5 ± 1.8
0.2 ± 0.1
p=0.045¹
p=0.14²
p=0.0143
0
0
92.2±63.6
Table 2. Gemcitabine lung and serum levels
¹ ILuP 160 mg/kg compared to iv 160 mg/kg; ²ILuP 320 mg/kg compared to
ILuP 160 mg/kg; 3 ILuP 320 mg/kg compared to iv 160 mg/kg; ILuP: isolated
lung perfusion; iv: intravenous.
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Figure 6.
Effluent ILuP with 160 mg/kg
Figure 7.
Effluent ILuP with 320
mg/kg
Discussion
Colorectal adenocarcinoma gives rise to a large number of pulmonary
metastases and therefore, it remains a serious health problem [1]. In case of
lung metastases no effective therapy is available resulting in long-term
survival. Many patients develop local recurrences after pulmonary
metastasectomy probably due to micrometastases present at the time of initial
therapy [1,16]. Systemic chemotherapy is dose-limited due to its severe side
effects. Isolated lung perfusion as a novel experimental technique is
promising as it can deliver a high local concentration without systemic side
effects. A rat model for pharmacokinetic and efficacy studies was developed
by Weksler [17] and modified in our laboratory in order to perform
experiments of ILuP in the Wag/Rij rat [13]. Several drugs like FUDR and
melphalan/TNF have already been tested with good results [6,7]. Recently, a
cytotoxic effect of GCB against HT29 colon carcinoma cells was observed
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by Tonkinson making it a promising agent for further studies of ILuP [9].
Our in vitro results show a higher sensitivity of CC531S adenocarcinoma
(IC50=23.6±1.1 nM) compared to HT29 colon carcinoma (IC50= 32.0±9.0
nM) [9]. Furthermore, toxicity of GCB was determined after treatment with
ILuP and iv infusion. Both the control groups of left ILuP and iv infusion had
a survival percentage of 100%. Intravenous infusion of 80 mg/kg and 160
mg/kg was sublethal with 70% and 80% survival respectively. All animals
died after iv infusion of 320mg/kg. However, all animals survived after ILuP
with doses of GCB up to 320 mg/kg which was the highest dose we could
administer because of maximal solubility of GCB. Only a significant
reduction in mean weight between group ILuP 20 mg/kg and ILuP 80 mg/kg
after pneumonectomy at three weeks is demonstrated. In this way, it has been
proven that treatment with GCB by ILuP is much less toxic compared to iv
infusion. Pharmacokinetic studies show significantly higher GCB lung levels
reached by ILuP with 160 and 320 mg/kg compared to iv infusion with 160
mg/kg. The pharmacokinetic benefit of ILuP has been confirmed and is in
agreement with results obtained before  [7, 18, 19].
Further studies will be performed to study efficacy of gemcitabine in an in
vivo model of lung metastases. More specifically, survival will be evaluated
in a rat model of unilateral lung metastases in which gemcitabine is
administered by isolated lung perfusion. In this specific model melphalan and
TNF have already been studied in our laboratory [7].
In conclusion, GCB is an effective drug against colon adenocarcinoma in
vitro. When given by isolated lung perfusion, higher lung levels are reached
and less toxicity is observed. In this way, GCB is a promising agent for use
by ILuP in the treatment of pulmonary metastases from colon
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adenocarcinoma. Further experimental and clinical studies are needed to
determine any survival benefit.
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Abstract
Background: Isolated lung perfusion (ILuP) proved to be superior for the
treatment of lung metastases compared to intravenous injection (IV).
However, its invasive character inhibits repetitive treatment. Blood flow
occlusion (BFO), as a regional therapy, with gemcitabine (GCB) was
evaluated in a rat model. Lung levels of GCB were examined with different
exposure times and flow rates and compared with ILuP and IV. Cell kill was
studied in vitro.
Methods: In vitro: Survival of CC531 adenocarcinoma cells was determined
after 10, 20 and 40 min of exposure to GCB. In vivo: 48 Wag/Rij rats
underwent BFO with GCB at a rate of 0.2 mL/min and 0.5 mL/min during
10, 20, 30 and 40 min. Statistical analysis was performed using the Student’s
t-test.
Results: In vitro: The dose of GCB resulting in 50% growth inhibition was
9.1 mg/mL, 7.2 mg/mL and 2.2 mg/mL after 10, 20 and 40 min exposure
respectively. In vivo: No significant difference in lung levels of GCB was
observed between a flow rate of 0.2 mL/min compared to 0.5 mL/min at any
exposure time point (p<0.05). Lung tissue was saturated after 20 min. BFO
resulted in a lower plasma levels and higher lung levels of GCB compared to
IV of the MTD of 40mg.
Conclusions: Growth inhibition of CC531 cells in vitro increased with
exposure time, while lung tissue was saturated after 20 minutes of BFO. No
difference in GCB lung levels were seen after BFO compared to ILuP.
Systemic exposure after IV was higher compared to BFO but did not result
in higher lung levels.
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Introduction
Isolated lung perfusion is an experimental surgical procedure for the
treatment of pulmonary metastatic disease in order to improve current 5-year
survival of around 40% [1]. The aim of this technique is to achieve high
local lung concentrations without systemic exposure. It can be a treatment
option to make bulky metastatic disease operable or to prevent intrathoracic
recurrences after removal of macroscopic metastatic disease of the lung.
Although the procedure itself is tolerated well [2], it is a highly invasive
procedure unlikely to be performed once again. Therefore, regional infusion
techniques like bronchial artery infusion or pulmonary artery perfusion
without control of the venous circulation are preferred since these
procedures can be repeated in time [3-4]. Only drugs with a good first-pass
effect can be selected since systemic exposure must be limited to a
minimum. The aim of the present study is to evaluate the in-vitro toxicity of
gemcitabine in an adenocarcinoma cell line, and to investigate lung and
serum levels of gemcitabine (GCB) during perfusion of the pulmonary
artery.
Material and methods
Animals
Male inbred WAG-Rij strain rats (weight, approximately 225g), obtained
from Iffa Credo (Brussels, Belgium), were used for all experiments. Animals
were treated in accordance with the Animal Welfare Act and the “Guide for
the Care and Use of Laboratory Animals” (NIH Publication 86-23, revised
1985). The rats were transported in sterile conditions, housed in suspended
mesh wired cages and fed a standard pellet diet ad libitum (standard rat
chow, Hope Farms, Woerden, The Netherlands). The experimental protocols
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were approved by the Institutional Animal Care and Use Committee,
University Hospital of Antwerp.
Cell line
The CC531s tumour cell line was used in this study to determine the
sensitivity for the cytotoxic effect of gemcitabine. This cell line was derived
from a chemically-induced adenocarcinoma of the colon of a WAG rat [5].
CC531s was cultured in RPMI-1640 medium, supplemented with 10% fetal
calf serum (Invitrogen, Merelbeke, Belgium). Cultures were maintained in
exponential growth in a humidified atmosphere at 37°C under 5% CO2 and
95% air.
Pulmonary artery perfusion
Pulmonary artery perfusion is performed as an isolated left lung perfusion
procedure without venous control [6]. Briefly, anaesthesia was induced with
isoflurane in a mixture of nitrous oxide (N2O) and oxygen (O2). Isoflurane
was administered in a concentration of 4%; N2O:O2 ratio was 3:1. Next, rats
were intubated by translaryngeal illumination and connected to a volume-
controlled ventilator at a rate of 75 strokes/min and a tidal volume of 10
mL/kg. After a left thoracotomy, the pulmonary artery is clamped with a
curved microclip. A PE-10 perfusion catheter was introduced into the
pulmonary artery. Perfusate was delivered through this catheter at a chosen
rate. At the completion of lung perfusion, the rat was killed by a venous cut
down of the caval vein.
The perfusate was temperature-controlled at 37ºC throughout the whole
perfusion. Rats were placed on a heating pad immediately after induction
and body temperature was kept constantly between 34°C and 37°C.
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Gemcitabine and gemcitabine processing and measurement
Gemcitabine (difluorodeoxycytidine, Ely Lilly Benelux, Brussels, Belgium)
perfusate solutions were prepared by reconstituting non-lyophilized powder
in the supplied diluent and performing appropriate dilutions with BHE prior
to the experiments.
Gas chromatography-mass spectrometry method was used for measuring
gemcitabine levels in lung tissue and serum. Deoxycytidine was used as an
internal standard. Samples were extracted over a Chrompack Spherisorb
ODS-2 reversed phase column [7,8].
Experiment 1: Cell survival after treatment with gemcitabine
Cells were harvested from exponential phase cultures by trypsinisation,
counted and plated in 48-wells plates. In order to assure exponential growth
during the experiments seeding density was 1000 cells per well. Following
plating and a 24 hr recovery period, cells were treated with gemcitabine (0,
10, 20 and 40 mM) dissolved in phosphate buffered saline (PBS) during 10,
20 or 40 minutes. PBS was added to control cells. Each concentration was
tested in sextuple within the same experiment. After incubation with
gemcitabine, cells were washed with drug free medium. Four days after
treatment the survival was determined by the sulforhodamine B (SRB) assay.
The SRB assay was performed according to the method of Skehan [9] and
Papazisis [10], with minor modifications. Culture medium was aspirated
prior to fixation of the cells by addition of 200 ml 10% cold trichloroactic
acid. After 1 hr incubation at 4°C, cells were washed 5 times with deionized
water. Then the cells were stained with 200 ml 0.1% SRB (ICN, Asse,
Belgium) dissolved in 1% acetic acid for at least 15 minutes and
subsequently washed 4 times with 1% acetic acid to remove unbound stain.
Chapter 4
66
The plates were left to dry at room temperature and bound protein stain was
solubilized with 200 ml 10 mM unbuffered TRIS base
(tris(hydroxymethyl)aminomethane) and transferred to 96 wells plates for
reading the optical density at 540 nm (Biorad 550 microplate reader,
Nazareth, Belgium).
The survival rates were calculated by: mean OD (optical density) of treated
cells / mean OD of control cells x 100%. The dose response curves were
fitted to the sigmoid inhibition model: E(survival)=1-(Cg / Cg+IC50g), using
Winnonlin (Pharsight, USA) to calculate IC50 values, the concentration
gemcitabine causing 50% growth inhibition.
Experiments were performed at least three times. All data are presented as
the mean ± standard deviation.
Experiment 2
Forty-eight Wag/Rij rats underwent pulmonary artery perfusion. These rats
were randomized into eight groups of 6 rats each. Gemcitabine (GCB) was
given at a concentration of 2.7 mg/mL during 10, 20, 30 and 40 minutes
respectively. Half of the groups were perfused at a rate of 0.5 mL/min while
the other groups were perfused at 0.2 mL/min. At the end of the procedure,
the lung was removed for determination of the wet-to-dry ratio and analysis
of GCB levels.
In 6 rats in the group with a flow rate of 0.2 mL/min perfused during 30
minutes serum samples were collected at 20 and 30 minutes for later analysis
of serum GCB levels.
Ten rats received the maximum tolerated intravenous dose of GCB, 160
mg/kg (40 mg per rat). Serum samples were collected at 6, 12, 15 and 21
minutes and stored at -70ºC for measurement of GCB lung and serum levels.
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Statistical Analysis
All data are presented as mean ± standard deviation (SD). Data were
analyzed using Student’s t-test. Significance was defined as p<0.05.
Results
Experiment 1
The dose-response curve is shown in figure 1. The IC50 value of CC531 for
gemcitabine at 10 minutes is 30.1±2.9 µM, at 20 minutes 21.7±3.3 µM and
at 40 minutes 6.5±3.1 µM.
Figure 1. Mean surviving fraction of CC531 colonies measured as a
function of gemcitabine concentration. Exposure times are 10, 20 and
40 minutes.
Experiment 2
Lung levels of GCB are stabilized after 10 minutes for an infusion rate of 0.5
mL/min, and after 20 minutes for a rate of 0.2 mL/min (Table 1 and Figure
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2). No difference in lung levels of GCB is seen at different times between
the two flow rates (Table 2).
No significant difference in wet-to-dry ratio was measured between both
flow groups or between different perfusion times (Figure 3).
No significant difference in serum levels of GCB was observed after
intravenous infusion in time (Figure 4, upper curve). Serum levels during left
lung perfusion at 0.2 mL/min (Figure 4, lower curve) were significantly
lower (p=0.02) while lung levels were significantly higher (p=0.003)
compared to intravenous infusion (0.2 microgram/g; reference 11).
Figure 2. Gemcitabine
lung levels in function
of exposure time
Figure 3. Wet-to-dry
ratio as a function of
perfusion time and
flow rate
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Figure 4. Gemcitabine serum levels after IV infusion and BFO (blood flow
occlusion). The IV treated rats received a bolus of 40 mg on t=0. Rats that
had BFO at 0.2 mL/min received 16 mg during 30 minutes (SD<0.025
mg/mL in the BFO group)
Flow rate Dose delivered Concentration delivered
0.5 mL/min
10 min: 13.3 mg
20 min: 26.7 mg
30 min: 40 mg
40 min: 53.3 mg
2.7 mg/mL
0.2 mL/min
10 min: 5.3 mg
20 min: 10.7 mg
30 min: 16 mg
40 min: 20.4 mg
2.7 mg/mL
Table 1. Dose and concentration of gemcitabine delivered by BFO (blood
flow occlusion)
Chapter 4
70
0.20mL/min 10 minutes 20 minutes 30 minutes 40 minutes
Mean±SD (mg/g) 0.63±0.13 0.94±0.21 0.97±0.41 1.35±0.6
p-value 0.0071 0.902 0.113
0.50mL/min 10 minutes 20 minutes 30 minutes 40 minutes
Mean±SD (mg/g) 0.62±0.37 0.90±0.53 0.76±0.38 1.19±0.77
p-value 0.171 0.632 0.133
p-value 0.96a 0.90 a 0.39 a 0.69 a
Table 2. Gemcitabine lung levels after BFO (blood flow occlusion) .
1 20 minutes vs 10 minutes; 2 30 minutes vs 20 minutes;3 40 minutes vs 30
minutes;a 0.50mL/min vs 0.20mL/min
Discussion
Complete surgical resection of pulmonary metastatic disease results in a 5-
year survival of around 40% [1]. Different novel target techniques to achieve
a higher local drug concentration in the lung are explored in an attempt to
improve this survival [12]. Isolated lung perfusion (ILuP) as a surgical
technique was already described in 1959 by Creech to obtain high lung
levels without systemic exposure [13]. In addition, it avoids metabolisation
by the liver or kidney. The technique was re-invented by Johnston during the
eighties [2] and tested in large animals by several investigators [2,14-16].
The lung proved to be an ideal organ since a complete vascular isolation was
possible without systemic exposure. The lung could also tolerate
temperatures as high as 44°C. Next with the development of rat models of
isolated lung perfusion, several drugs were tested for their tumour efficacy.
All these experiments showed isolated lung perfusion superior to intravenous
infusion, both pharmacokinetically and therapeutically as well [17-21]. This
resulted in some phase I trials of isolated lung perfusion with different
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agents, some of them already finished [22-25]. The main disadvantage of the
technique of isolated lung perfusion is its invasive character. It necessitates a
thoracotomy while its effect has to be exerted during a single procedure.
Therefore, it is doubtful that ILuP becomes useful to treat bulky metastatic
disease or to make inoperable patients curable. Regional infusion techniques
like bronchial artery infusion or pulmonary artery perfusion have the
advantage they can be repeated, but drugs need to have a good first-pass
effect in order to minimize systemic leakage through an open venous
circulation. Since lung metastases are mainly supplied by the pulmonary
artery, pulmonary artery perfusion by endovascular way is the preferred
technique. Of these techniques, blood flow occlusion (BFO) as described by
Wang [4] proved to be superior, and has been tested with success for
doxorubicin [4, 26]. The aim of this study was to assess the use of
gemcitabine by BFO, and compare it with ILuP which was tested in a
previous experiment [11]. As a first step, the IC50 of gemcitabine was
explored for an adenocarcinoma cell line of which a rat model of pulmonary
metastatic disease is present at our laboratory [20]. These in-vitro
experiments showed that 50% of the cells were killed between a
concentration of at least 2.2 mg/mL for 40 minutes and 7.2 mg/mL for 20
minutes. In a next experiment, plasma and lung concentrations were
compared between BFO, IV injection and ILuP. The concentrations after
ILuP were extrapolated from a previous experiment. ILuP with 40 mg (160
mg/kg) resulted in lung levels of 1.5 µg/g of GCB [11]. The flow rate of 0.5
mL/min used for the ILuP experiments was chosen for the BFO as well. In
addition, a lower perfusion rate (0.2 mL/min) was selected in order to reduce
the total amount of drug given for the same perfusion time (Table 2). The
concentration of GCB within the perfusate was the same for all BFO groups.
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For the intravenous treated animals, the maximum tolerated dose of 160
mg/kg was given. In this way, maximum systemic exposure achieving the
highest lung levels after intravenous injection were compared with regional
techniques like ILuP and BFO. Although the same concentration was
delivered by BFO in all groups, the rate of 0.2 mL/min resulted in the same
final lung levels compared to 0.5 mL/min for all groups, while the total
amount of GCB given was only half. Although the dose of GCB after
intravenous injection (40 mg; MTD) was significantly higher compared to
BFO at a rate of 0,2 ml/min which resulted in higher serum levels, lung
levels after intravenous injection were significantly lower (0.2 µg/g)
compared to BFO. Gemcitabine lung levels after ILuP for 30 minutes with a
dose of 40 mg (1.5 µg/g; reference 11) were not different from BFO at the
lowest rate for 20, 30 and 40 minutes. However, the total amount of GCB
given was less compared to ILuP.
In conclusion, our experiments demonstrate that the same gemcitabine levels
in lung tissue can be obtained using ILuP or BFO perfusion. Compared with
IV drug administration, the plasma levels are lower while the lung tissue
concentrations are higher with BFO perfusion. Compared to ILuP, a higher
and non-toxic systemic exposure is present after BFO while no different lung
levels are seen for a lower total amount of GCB given. In addition, BFO is
technically less demanding and can be used clinically by catheterization of
the pulmonary artery.
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Abstract
Background: Isolated lung perfusion (ILuP) with melphalan (MN) is
superior to intravenous infusion for the treatment of pulmonary carcinoma
and sarcoma metastases. However, it is unknown whether a bolus injection
of MN into the perfusion circuit or ILuP with a fixed concentration of MN
will result in the highest lung levels.
Methods: ILuP with 0.5mg MN was performed in Wag/Rij rats for 30
minutes either by a single-pass system (SP) (fixed concentration) (n=10) or
by reperfusion (RP) (bolus injection) (n=10). In a separate experiment, rats
were perfused with blood as the perfusate. In a third experiment, tumour
levels were compared between SP, RP or intravenous therapy with a dose of
0.5mg. For induction of pulmonary metastases, 0.5x10E6 single
adenocarcinoma cells were injected intravenously and therapy was given on
day 30. For comparison of drug concentrations, unpaired Student’s t test was
applied. Statistical significance was accepted at p less than 0.05.
Results: Lung perfusion studies were successfully performed without
systemic leakage. Temperature of perfusate and rats was 34-37°C. A
significantly higher hematocrit (mean: 27.9) compared with buffered starch
(mean: 2.5) did not result in higher MN lung levels or lower wet-to-dry ratio.
Tumour levels were significantly higher after ILuP compared with
intravenous therapy. However, no difference in tumour and lung levels was
seen between single-pass and reperfusion.
Conclusion: Both ILuP techniques resulted in significant higher MN lung
levels than after intravenous therapy. Since no difference was seen between
single-pass and recirculating perfusion, MN can be injected as a bolus into
the closed perfusion circuit.
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Introduction
Although surgical resection remains the primary treatment for the treatment
of pulmonary metastases, the 5-year survival is only 30% to 40% [1].
Systemic chemotherapy is of limited value, and high-dose regimens in order
to increase response rates are limited by severe systemic side effects. To
achieve higher local concentrations in the lung with minimal systemic
exposure, isolated lung perfusion (ILuP) can be a promising technique. First
described by Creech and associates in 1958 [2], numerous agents like
doxorubicin, tumour necrosis factor, cisplatin, 5FU and melphalan have been
tested since, both in large animals and small animals as well [3-7]. For
melphalan, both acute and long-term experiments showed reversible short-
term toxicity, minimal long-term toxicity and excellent pharmacokinetic
profiles. Compared with intravenous treatment, ILuP resulted in a
significantly higher eradication of tumour nodules and a significantly longer
survival time. These findings have been confirmed for both carcinoma and
sarcoma lung metastases models in the rat [7-9]. In addition, isolated limb
perfusion with melphalan showed synergistic effects with tumour necrosis
factor for melanoma and sarcoma [10]. Because isolated lung perfusion in
patients with tumour necrosis factor was tolerated up to a dose of 6 mg,
melphalan seems to be a promising agent for further clinical studies, as a
single agent or in combination with tumour necrosis factor. So far, all
isolated lung perfusion experiments with melphalan were single-pass
perfusions, which is an excellent technique for pharmacokinetic studies.
Clinical ILuP, however, is performed with a closed extracorporeal circuit
with a priming volume of 1.0 L or less, mainly to reduce the amount of
expensive perfusate fluids needed compared with single-pass perfusions.
However, it is unknown whether the dose or the concentration of melphalan
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will result in the highest lung levels. If it is the concentration that will
determine this level, it will be very difficult to maintain the concentration
constantly in a closed circuit with reperfusion. A dilutional effect will
develop during perfusion, because a lower concentration at the venous side
will be mixed with the higher concentration at the arterial side. In
preparation for clinical phase I studies, these pharmacokinetic parameters
need to be defined, and therefore, single-pass left lung ILuP (SP) was
compared with recirculating isolated left lung perfusion (RP) in a rat model
to determine the maximal final melphalan levels in lung and tumour tissue.
With the single-pass technique, a constant concentration is presented to the
lung, whereas in the reperfusion circuit, a bolus (a dose) is injected into the
circuit, but the concentration within the perfusate is changing continuously.
The total amount delivered is the same but the volume of the perfusate will
be different. In addition, blood as a perfusate was used in order to study the
effect of the presence of red blood cells on the maximal melphalan tissue
concentration because red blood cells can act as a carrier for MN, and to
investigate the development of pulmonary oedema [11].
Material and Methods
Animals
Male inbred WAG-Rij strain rats (weight, approximately 200g), obtained
from Harlan-CPB (Zeist, The Netherlands), were used for all experiments.
Animals were treated in accordance with the Animal Welfare Act and the
“Guide for the Care and Use of Laboratory Animals” (NIH Publication 86-
23, revised 1985). The rats were transported in sterile conditions, housed in
suspended mesh wired cages and ad libitum fed a standard pellet diet
(standard rat chow, Hope Farms, Woerden, The Netherlands). The
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experimental protocols were approved by the Institutional Animal Care Use
Committee, University Hospital Antwerp.
Tumour
The CC531S tumour cell line was used for assessment of MN levels in lung
metastases. This cell line was derived from a chemically induced
adenocarcinoma of the colon of a WAG rat. CC531S was cultured in
complete medium and maintained by serial passage. Complete medium
consisted of RPMI-1640 medium, supplemented with 10% heat activated
fetal bovine serum (FBS, both from Life Technologies, Merelbeke,
Belgium), 2 mmol/L glutamine, 50 mg/mL streptomycin and 50 U/mL
penicillin [3].
Induction of lung metastases
CC531S cells were prepared for injection by dispersal with a solution of
0.25% ethylinediamine tetraacetic acid (EDTA) and 0.05% trypsin in Hank
’s balanced salt solution (HBSS). Cell viability was determined with a
tryptan blue exclusion method using a hemocytometer [8]. Because the
original technique for induction of lung metastases resulted in small
pulmonary metastases not suitable for pharmacokinetic analysis, a new
model was developed. Ten rats were injected with only 500.000 CC531S
adenocarcinoma cells in 1mL of RPMI 1640 into the left femoral vein. Half
of the rats were killed on day 15 and half on day 30. On day 15, only a few
tumour nodules were visible still too small for selective excision. However,
on day 30 large metastases were visible macroscopically as separate nodules,
easily to excise for further analysis.
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Blood
In order to perfuse the lung with buffered hetastarch (BHE) enriched with
red blood cells, many rats need to be sacrificed for one experiment since
only 6 mL/100 g whole blood can be retrieved from a single rat. Because red
blood cells (RBC) seem to be of surprising uniformity in all mammals [10],
we were not restricted to the use of rodent RBCs, and washed rabbit
erythrocytes were chosen to enrich the perfusate. Rabbit blood was drawn
directly from the left ventricle of living rabbits after systemic heparinization.
The red cells were processed within a few hours, using sterile techniques to
remove plasma, white cells and platelets. The blood was spun at 3,500g for
10 minutes and the supernatant plasma was removed. The cells were diluted
with 0.9% saline and spun in the same way as in the first process. The red
blood cells were then diluted with BHE solution to a hematocrit of around
30%. Thereafter, leucocytes were removed through a commercially available
leukocyte filter.
Technique of Single-Pass Isolated Left Lung Perfusion (SP) and Isolated
Left Lung Reperfusion (RP)
Single-pass isolated left lung perfusion was performed according to the
technique as described by Hendriks et al [12]. Briefly, anaesthesia was
induced with isoflurane. Rats were intubated by translaryngeal illumination
and connected to the ventilator. Isoflurane was titrated between 0.5% and
1.5% according to muscle relaxation, heart rate and pupil size. Ventilation
was accomplished with a volume-controlled ventilator at a rate of 75
strokes/min and a tidal volume of 10 mL/kg. After a left thoracotomy, the
lung and rib retractor were placed anteriorly and the hilum was dissected
free. The bronchus was deprived from its surrounding tissue in order to
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exclude the bronchial arterial flow to the lung. After clamping the
pulmonary artery and vein with curved microclips, a 16-G Angiocath was
placed through the chest wall. A PE-10 perfusion catheter was introduced
into the chest through the Angiocath and secured by a 4/0 silk tie after
insertion into the pulmonary artery. Perfusate was delivered through this
catheter. In addition, a pulmonary venotomy was performed and two venous
catheters (PE-90) were placed into the superior and inferior pulmonary vein
to collect the venous effluent. In the case of single-pass perfusion, the
effluent is discarded at the venous side. With isolated left lung reperfusion,
the venous effluent is collected into the warm water bath, and from this bath
reinfused into the pulmonary artery (fig. 1).
For both SP and RP, the perfusate is temperature-controlled throughout the
whole perfusion. Rats were placed on a heating pad immediately after
induction, and body temperature was kept constantly between 34°C and
37°C.
In all experiments, animals were perfused on the left side for 25 minutes at a
rate of 0.5 mL/min, followed by a 5-minute washout with buffered
hetastarch (BHE) at 0.5 mL/min.
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Figure 1. The rat was placed on a heating pad after orotracheal intubation
and connected to a ventilator. Through a left thoracotomy, the pulmonary
artery and veins were cannulated. The perfusate was drawn from a warm
water bath by a roller pump and infused into the pulmonary artery. For
single-pass perfusion, the effluent coming out of the pulmonary veins was
discarded. In case of reperfusion, the effluent was sent back by the roller
pump to the warm water bath and recirculated into the pulmonary artery. A
= reperfusion circuit; B = single-pass perfusion.
Melphalan (Alkeran, 50 mg/vial, Wellcome, Waterloo, Belgium) perfusate
solutions were prepared by reconstituting lyophilized powder in the supplied
diluent and performing appropriate dilutions with BHE prior to the
experiments.
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Experiment 1: Single-pass Isolated Lung Perfusion versus Isolated
Lung Reperfusion with buffered starch and red blood cells as
perfusates
Twenty-eight rats were randomized into four groups. Group 1 (n=10) and
group 3 (n=4) had SP with 0.5 mg of MN, whereas group 2 (n=10) and
group 4 (n=4) had RP with 0.5 mg of MN. While group 1 and 2 had BHE as
the perfusate, this was BHE enriched with red blood cells (RBHE) for
groups 3 and 4. During perfusion, pulmonary effluent samples were
collected at 5-minute intervals throughout the perfusion for groups 1 and 2.
At the completion of a 25-minute MN perfusion and 5-minute BHE washout,
the left lung was removed and frozen at   -70°C for later analysis.
Experiment 2: Determination of melphalan levels within the lung
metastases
Twelve rats were randomized into three groups (n=4 each). On day 0, all rats
received 500,000 CC531S adenocarcinoma cells in the left femoral vein. On
day 30, group 1 had SP with 0.5 mg of MN and group 2 had RP with 0.5 mg
of MN. Group 3 received 0.5 mg of intravenous MN. The left lungs of group
1 and 2 were perfused for 25 minutes with BHE as the perfusate followed by
a 5-minute BHE washout. Thirty minutes after the onset of therapy,
pulmonary metastases in all groups were separated from normal lung tissue
and frozen at -70°C for later analysis.
Melphalan Processing and Measurement
Gas chromatography-mass spectrometry described by De Boeck et al. was
used for measuring melphalan levels in lung tissue and serum [13]. P-[Bis(2-
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chloroethyl)amino]-phenylacetic acid methyl ester was used as an internal
standard. Samples were extracted over trifunctional C18 silica columns.
Tabel 1. Hematocrit and temperature
a group 1 compared to group 2
b group 2 compared to group 4
c group 3 compared to group 1
d group 3 compared to group 4
SP: single-pass perfusion
RP: reperfusion
Statistical Analysis
All data are presented as mean ± standard deviation (SD). Comparison
between groups was done by an unpaired Student’s t-test. Significance was
defined as p less than 0.05.
Results
Mortality
All rats survived injection of tumour cells and the procedure related survival
was 100% for all experiments.
group procedure n Temp
reservoir (ºC)
Temp rat
(ºC)
hematocrit W/D
1 SP, BHE 4 35.8±0.5
(NSa)
35.8±1.1
(NSa)
1.4±0.6 6.4±0.5
(NSa)
2 RP, BHE 4 36.0±0.8
(NSb)
35.1±0.8
(NSb)
3.6±1.1
(p<0.001b)
6.5±0.5
(NSb)
3 SP, RBC 4 35.5±1.0
(NSc)
34.6±0.5
(NSc)
27.8±3.2
(p<0.001c)
6.5±0.7
(NSc)
4 RP, RBC 4 36.6±0.5
(NSd)
34.8±1.0
(NSd)
28.1±1.6 6.6±0.7
(NSd)
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Experiment 1
The temperature of the reservoir and the rats was not significantly different
between groups (Table 1).
Hematocrit levels were significantly lower for group 1 and 2 (BHE
perfusate) compared with groups 3 and 4 (red blood cell-BHE perfusate). No
significant difference was seen in wet-to-dry ratios between the groups.
(table 1).
Group Procedure n Left lung (µg/g) p
1 left SP, BHE 10 29.3±11.8 NSa
2 left RP, BHE 10 27.1±11.4 NSb
3 left SP, RBC 4 18.7±12.9 0.09c
4 left RP, RBC 4 17.3±10.2 NSd
Table 2. Left lung melphalan levels after perfusion with 0.5 mg MN
a group 1 compared to group 2
b group 2 compared to group 4
c group 3 compared to group 1
d group 3 compared to group 4
SP: single-pass perfusion
RP: reperfusion
MN: melphalan
No significant difference was seen in the left lung MN levels of rats treated
with single-pass compared to reperfusion (Table 2). Also no statistically
significant difference was observed in left lung MN levels of rats treated
with reperfusion with RBC-BHE as the perfusate compared with BHE, or
between single-pass and reperfusion with RBC as the perfusate (Table 2). A
significant difference was seen in rats treated with single-pass perfusion with
RBC-BHE compared with BHE. Figure 2 shows MN effluent levels over
time.
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MN effluent levels
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Experiment 2
Tumour melphalan levels of intravenously treated rats were significantly less
compared with single-pass perfusion or reperfusion (Table 3). However, no
statistically significant differences in final tumour melphalan levels were
seen between a single-pass perfusion compared with a recirculating
procedure (p=0.133) (Table 3).
Table 3.
Lung metastases
melphalan levels
(acompared with
group 3)
Figure 2.
Melphalan
effluent levels
Comment
While the lungs are the most common site of metastases [14], it is known
that for sarcoma and carcinoma metastases, up to 50 % of the patients have
recurrent disease exclusively in the lung after resection of the primary
disease, probably due to the presence of micrometastases at the time of the
initial operation [1,15]. Recurrent disease can be inoperable due to size,
number or location of these lung metastases. Therefore, it is important to
have local control of microscopic disease after surgical resection of visible
Group procedure n Tumour (µg/g) p
1 SP 0.5 mg MN 4 8.3±5.9 0.031a
2 RP 0.5 mg MN 4 16.6±7.5 0.014a
3 iv 0.5 mg MN 4 1.5±0.06 NS
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metastatic disease in order to achieve a long-term survival. Systemic
chemotherapy has been ineffective because it is limited by severe systemic
side effects. Isolated lung perfusion can deliver very high doses of
chemotherapy with minimal systemic exposure, while avoiding
metabolisation of the drug in liver or kidney. Therefore, isolated lung
perfusion seems to be a promising technique to eradicate micrometastatic
disease at the time of surgical resection of macrometastatic disease in order
to prevent the development of recurrent disease.
Since the early 1980s, the technique of isolated lung perfusion has been
tested with success in large animals like dogs and pigs [4,16,17]. Later, rat
models were developed for tumour efficacy studies with different
chemotherapeutic agents. Numerous agents like tumour necrosis factor,
FUDR, cisplatin, and doxorubicin have been tested with success in these rat
models, and single-pass left lung perfusion was the only technique used [18].
A single-pass system was selected as a procedure for technical reasons and
because this method facilitates drug kinetic studies by ensuring a constant
drug concentration in the perfusate. Technically seen, it is very demanding to
cannulate the pulmonary veins of the rat and even more difficult to restore
the venotomy after perfusion in case of survival experiments. Therefore, no
cannulation is performed in the single-pass technique, but the effluent is
discarded by a suction catheter and closure of the small venotomy is
accomplished by pressure after the procedure [19].
Weksler and associates showed in their rat model of ILuP that the perfusate
doxorubicin concentration and duration of perfusion were the only factors
determining the final lung concentration of doxorubicin. The dose of
doxorubicin, and the total amount and rate of perfusion were not important
in determining the final lung doxorubicin concentration [20]. They did not
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investigate these values in a model of pulmonary metastases. Their studies
were finalized by a phase I dose-escalating trial of ILuP with doxorubicin in
sarcoma metastases [21]. For this clinical study, a recirculating perfusion
system was preferred because it minimizes the amount of perfusate and drug
needed, vascular isolation becomes more complete and greater flexibility is
obtained in regulation of the perfusion environment [22]. The drug was
added to the circuit as a bolus and not as a constant concentration. The fact
that drug concentration was crucial in the rat experiments for the final lung
concentration might explain the large variations in perfusate and lung levels
of doxorubicin between patients receiving the same amount of drug [21]. It
also shows the difficulty of calculating the amount of drug to give each
patient. In contrast with isolated limb perfusion, where doses are calculated
by the amount of water displaced by the limb, no such value is available is
available for lung perfusion studies [10].
In our laboratory, a rat model of isolated single-lung perfusion was
developed, and experiments with melphalan were extensively performed in
preparation of human clinical trials since 1995. These animal experiments
showed low operative mortality and negligible long-term injury to the lungs
[7,8]. We have shown that ILuP with melphalan results in significantly
higher final lung melphalan levels compared with a high intravenous
injection of melphalan [7]. Studies of experimental pulmonary metastases
showed statistically significant eradication of experimental sarcoma and
carcinoma metastases in rats undergoing isolated single-lung perfusion with
melphalan compared to intravenous therapy [7-9]. In preparation of a clinical
phase I dose-escalating trial of isolated lung perfusion with melphalan, a
number of questions were unanswered. First, it is unknown how the dose
should be calculated because lung mass can be very different between two
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patients. No value such as limb volume for isolated limb perfusion is
available for the lung. Second, in all clinical studies performed so far, a
closed circuit was used in order to lessen the amount of perfusate needed and
to control values like flow, air leakage and temperature. In these studies, the
drug was given as a bolus into the circuit proximal to the pulmonary artery
(a dose), but not offered to the lung as a constant concentration. However,
Weksler and associates demonstrated that drug concentration was crucial for
the final lung concentration of doxorubicin [20]. For melphalan these values
were not known. In this study, both lung and tumour MN levels were
determined, as no correlation has been made between normal lung and
tumour tissue. Tumour melphalan levels were significantly higher in the
single-pass group compared with MN levels in the intravenous group.
However, there was no significant difference between single-pass and
reperfusion group, and a steady concentration was reached after 15 minutes.
So, not the concentration but the total amount of drug was critical for the
final lung concentration, which is in contrast with rat studies of doxorubicin
[20]. In this way, it seems that a bolus of MN into the circuit will result in
the same final lung and tumour levels compared with single-pass perfusion
with a fixed concentration. A higher concentration within the lung was
achieved compared with the tumour. In the reperfusion group, a higher
concentration was reached in the tumour compared with the single-pass
group, but the difference was not significant.
So far, both experimental and clinical studies are only available for
doxorubicin. Although doxorubicin has proven to be a superior agent for
isolated lung perfusion studies compared with intravenous therapy, the
clinical dose-escalating study was disappointing, and for the highest dose,
important side effects were seen [21]. Putnam and associates showed smaller
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dose increases can result in lower morbidity [23]. The highest dose used by
Burt and associates, 80 mg/kg, was twice the lower dose, whereas Putnam
and associates included a dose of 60 mg/kg without any morbidity. These
two studies show that pharmacokinetics will behave totally differently from
the three-compartment model described for intravenous administration of
chemotherapy. These dose-escalating studies should be performed for every
agent that was promising in animal studies. The human isolated lung model
described by Linder and associates extrapolates animal studies into the
human situation, and provides useful pharmacokinetic information before
starting phase I dose-escalating trials [24].
No significant differences in wet-to-dry ratios were seen between the groups
in our experimental study (mean of all groups, 6.5 ± 0.5). Because both the
pulmonary veins were cannulated, the wet-to-dry ratios were higher
compared with results obtained by Weksler and associates [20]. In our
previous work, we used BHE as the perfusate fluid of choice based on the
experiments by Weksler and associates [20]. These experiments did not
investigate the addition of RBCs within the perfusate. However, it is possible
that these RBCs will act as a better carrier for melphalan [25] and will
diminish the amount of pulmonary edema during perfusion. In addition,
RBCs will decrease anoxia-induced pulmonary damage. Despite this
hypotheses, no significantly higher MN levels were reached with RBCs
within the perfusate compared with BHE, and no difference was seen in the
amount of pulmonary edema. Therefore, BHE will remain the perfusate fluid
of choice for both laboratory and clinical studies.
In conclusion, no difference in final lung concentration was seen between
single-pass left lung perfusion and isolated left lung reperfusion. The single-
pass left lung perfusion acted as a model to deliver a fixed concentration of
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drug to the lung. This was compared with recirculating isolated lung
perfusion as a model of a closed circuit, in which a bolus was injected at a
certain time point. The total amount of drug delivered in the two models was
identical. In addition, the administration of RBCs to the perfusate did not
increase the final lung concentration, and the amount of pulmonary oedema
was not statistically significant. These findings will simplify isolated lung
perfusion with melphalan because buffered starch will be the perfusate of
choice and melphalan can be injected as a bolus into the circuit, after
stabilization of the main values, such as temperature, flow, and leakage.
Dose-escalating phase I studies will determine whether melphalan is a useful
agent in the setting of isolated lung perfusion.
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Abstract
Objective: Chronic toxicity and efficacy after isolated left lung perfusion
(ILuP) with gemcitabine (GCB) were studied in a rat model of metastatic
pulmonary adenocarcinoma.
Methods: Toxicity: Seventy-five rats were randomized between intravenous
injection (IV) and ILuP on day 0. Doses of 20, 40, 80, 160 and 320mg/kg
GCB and buffered hespan were given in the ILuP arm. Doses of 40, 80, 160
and 320mg/kg (n=6) and buffered hespan were given in the IV arm. At day
90, lungs were harvested and processed for histologic analysis. Efficacy: On
day 0, thirty-three rats were randomized into five groups: Groups 1 (n=5)
and 2 (n=10) received tumour cells IV for induction of bilateral lung
metastases, whereas group 2 received IV treatment with GCB 160mg/kg at
day 7 (n=10). Groups 3, 4 and 5 underwent a 10-min occlusion of the right
pulmonary artery during tumour cell injection for induction of unilateral left
lung metastases. On day 7, group 3 received no treatment (n=4). Group 4
and 5 underwent left ILuP with GCB 320mg/kg and 480 mg/kg (n=7 each).
Results: Toxicity: After IV treatment, all rats receiving GCB 320mg/kg died
within one week while GCB 160mg/kg had a survival rate of 60%. After
ILuP with GCB 160mg/kg and GCB 320mg/kg survival rates were 83% in
both groups. A slight increase in collagen deposits was seen for ILuP
320mg/kg after 3 months compared to controls. Efficacy: Median survival of
group 4 (38±4 days) was significantly longer compared to controls (group 3;
28±2 days; p=0.02).
Conclusions: ILuP with GCB prolongs survival in experimental metastatic
adenocarcinoma while no major acute or chronic toxicity is observed.
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Introduction
Colorectal adenocarcinoma is a major cause of pulmonary metastases [1].
Complete resection for pulmonary metastases has extensively been studied
but results in a 5-year survival of approximately 40 % for pulmonary
metastases from colorectal adenocarcinoma [2]. Systemic chemotherapy
does not have a significant effect on long-term survival and results in severe
side effects like bone marrow depression and hair loss [3]. In order to
prevent systemic side effects and to obtain higher local drug concentrations,
Weksler et al. developed a rat model of Isolated Lung Perfusion (ILuP) as a
new strategy for the treatment of pulmonary metastases. This technique was
subsequently modified by Wang [4,5]. ILuP is especially focused on
destroying micrometastases and can be combined with metastasectomy to
remove manually palpable metastases. In preparation of human studies
several drugs have now been tested in this rat model with different success
rates. Melphalan proved to be the most active drug tested in the rat model of
metastatic pulmonary sarcoma and colorectal adenocarcinoma [6,7]. In the
latter study from our laboratory unilateral pulmonary metastases were
induced by intravenous (IV) injection of adenocarcinoma cells while
clamping the right pulmonary artery during ten minutes in order to induce
metastases on the left side. Rats had left ILuP with melphalan at day seven
and survival was compared to rats which were IV treated. Mean survival was
81±12 days compared to 28±3 days in the IV treated group while some
animals of the ILuP group were even disease-free histologically after
sacrification after 90 days [7]. Significantly more alveolar cell hyperplasia
was noted in the acute phase after ILuP with melphalan [7]. Ueda et al.
confirmed the mild acute toxicity with melphalan but did not observe long-
term adverse effects [8]. Due to these hopeful results a phase I trial has been
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started in our hospital in cooperation with the Sint Antonius Hospital
(Nieuwegein, the Netherlands).
Gemcitabine (GCB) is a deoxycytidine analogue with single agent activity in
non-small cell lung carcinoma, colorectal adenocarcinoma and carcinoma of
the pancreas, breast and ovary [9-12]. Although pulmonary toxicity of
gemcitabine has only seldom been reported and is usually mild, respiratory
distress syndrome and interstitial pneumonitis after IV GCB infusion have
been described [13,14]. In a recent study we determined the survival of
CC531S adenocarcinoma cells exposed to different concentrations of GCB.
The IC50 value which is the concentration of GCB resulting in a growth
inhibition of 50% was 23.6 nM which means that the CC531 S cells are
highly sensitive to GCB [15]. Furthermore, this study showed the maximally
tolerated dose after ILuP with GCB to be higher compared to intravenous
therapy resulting in significantly higher lung levels after ILuP [15].
No data are available on efficacy and chronic pulmonary toxicity of ILuP
with doses of GCB that are much higher than the doses of the currently used
IV therapy. Therefore this study aimed to investigate the efficacy and the
histological side effects of GCB on lung tissue after ILuP compared to
systemic administration.
Material and methods
Animals
Male inbred Wag-Rij strain rats (weight, approximately 250g), obtained
from Iffa Credo (Brussels, Belgium), were used for all experiments. The
animals were treated in accordance with the Animal Welfare Act and the
“Guide for the Care and Use of Laboratory Animals” (NIH Publication 86-
23, revised 1985). The rats were transported in sterile conditions, housed in
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suspended mesh wired cages under standard laboratory conditions and ad
libitum fed a standard pellet diet (standard rat chow, Hope Farms, Woerden,
The Netherlands). The experimental protocols were approved by the
Institutional Animal Care Use Committee, University of Antwerp.
Technique of Left Isolated Lung Perfusion
Isolated left lung single-pass perfusion was performed according to the
technique described by Wang [5]. This technique was modified in our
laboratory and full details have been reported previously [15-17]. Briefly,
rats were anaesthetised with isoflurane in a mixture of nitrous oxide (NO2)
and oxygen (O2). Isoflurane was administered in a concentration of 4% and
the NO2:O2 ratio was set to 3:1. After 5 minutes, rats were intubated with a
16-gauge Insyte-W catheter by translaryngeal illumination and afterwards
ventilated with a volume-controlled ventilator (Harvard Rodent Ventilator,
South Natick, MA) [15]. Once connected to the ventilator, the NO2:O2 ratio
was 1:1 (0.5 L/min) and the rate of ventilation was 75 strokes/min with a
tidal volume of 10 mL/kg. Subsequently, the left chest was shaved and a left
thoracotomy between the third and fourth intercostal space was performed.
After placing a rib retractor, the left lung was luxated anteriorly and the
pulmonary artery and vein were dissected free before they were clamped
with curved microclips. A PE-10 perfusion catheter (Becton Dickinson,
Bornem, Belgium) was introduced into the chest through a 16-G Angiocath,
which was placed through the chest wall. The PE-10 catheter was inserted
into the pulmonary artery and fixed with a 4/0 silk tie. The perfusate was
delivered through this catheter. The effluent was sucked by a catheter at the
venous side in proximity of the venotomy.
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In all experiments, rats were perfused during 25 minutes followed by a 5-
minute washout with buffered starch at a rate of 0.5 mL/min. GCB
(gemcitabine, Eli Lilly Benelux) solutions were prepared by reconstituting
lyophilized powder in the supplied diluent and performing appropriate
dilutions with buffered hydroxy-ethyl starch (Haes Steril, BHE). After
perfusion the catheter was removed and the arteriotomy was closed with a
transverse suture (10/0 Ethilon, Ethicon, Belgium). The microclamps were
removed and the lung was returned into its anatomic position. Pressure was
applied using moist gauze over the lung in order to tamponade the bleeding
from the venotomy. A 16-gauge catheter connected to a 50-mL syringe was
introduced into the left chest cavity through a separate puncture wound to
facilitate lung reexpansion. The thoracotomy incision was closed in three
layers with 4/0 vicryl (Ethicon, Belgium). The animal was supplied with
room air until it began to breathe spontaneously. Subsequently, the pleural
drain and the endotracheal tube were removed.
Tumour
The CC531S tumour cell line was used to induce lung metastases. This cell
line was derived from a chemically induced adenocarcinoma of the colon of
a WAG rat [18]. CC531S was cultured in complete medium and maintained
by serial passage. Complete medium consisted of RPMI-1640 medium,
supplemented with 10% heat activated fetal bovine serum (Life
Technologies, Merelbeke, Belgium), 2 mmol/L glutamine, 50 mg/mL
streptomycin and 50 U/mL penicillin.
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Induction of pulmonary metastases
Unilateral and bilateral lung metastases were induced according the method
which was extensively described before [19-21].
Briefly, after anaesthesia and intubation, a right thoracotomy was performed
through the third intercostal space for induction of unilateral lung
metastases. Under microscopic view a longitudinal incision was made along
the posterior side of the superior caval vein in order to visualize the right
pulmonary artery which was subsequently clamped. After repositioning the
rat, a tumour cell suspension (2.0 ´ 106 viable CC531 S adenocarcinoma
cells in 1 mL of RPMI) was injected IV into the left femoral vein which was
prepared in advance. The groin incision was closed with a running suture of
4-0 vicryl (Ethicon, Belgium). After a 10-minute occlusion of the right
pulmonary artery, the clamp was removed and the thoracotomy was closed
as described above.
For induction of bilateral metastases a tumour cell suspension (2.0 ´ 106
viable CC531 S adenocarcinoma cells in 1 mL of RPMI) was injected into
the left femoral vein. The groin incision was closed as described above.
Histopathological examination
All lungs were prefixed in 4% formaldehyde in a mixture of 0.1M
natriumcacodilaat (pH=7.4) and 1% CaCl2. Samples taken for light
microscopy investigations were dehydrated with ethanol, cleared with toluol
and embedded in paraffin wax. Sections of 4 mm thick were processed by
Masson Trichrome staining in order to assess collagen fibrosis.
The lung sections were evaluated by a pathologist (P.B.V) without
knowledge of the respective treatment schedule. Collagen fibrosis in the
alveolar septa was graded by own definitions, ranging from absent over mild
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to moderate fibrosis. Normal lung tissue is shown in figure 1a. The collagen
fibres surrounding larger bronchi were taken as an internal control of the
staining intensity. Mild fibrosis was defined as slight broadening of some
alveolar septa due to collagen fibres (figure 1b). Moderate fibrosis was
defined as easily recognizable broadening of a considerable amount of
alveolar septa due to collagen deposition (figure 1c). Pleural fibrosis was
defined as broadening of the pleura. Reproducibility was tested by re-
evaluation of the slides with an interval of one week by the same pathologist.
In less than 10%, a shift of grade 3 to 2 or vice versa was observed.
Statistical analysis
Survival rates were assessed by Kaplan-Meier analysis and differences in
survival by a log rank test. Toxicity data were statistically evaluated using a
c2-test. Significance was accepted at p < 0.05.
Experiment 1: Chronic pulmonary toxicity of gemcitabine in rats
Seventy-five rats were randomized into eleven groups. Groups 1 to 5 had left
ILuP with 20 mg/kg (n=3), 40 mg/kg (n=6), 80 mg/kg (n=6), 160 mg/kg
(n=6) and 320 mg/kg (n=6) of GCB respectively. Group 6 (n=6) had ILuP
with buffered starch. Rats were perfused during 25 minutes followed by a 5-
minute washout. After three weeks a right pneumonectomy was performed
to assess left lung function. Groups 7 to 10 were infused IV with 40 mg/kg
(n=10), 80 mg/kg (n=10), 160 mg/kg (n=10) and 320 mg/kg (n=6) of GCB
respectively. Group 11 (n=6) was infused IV with saline (0.9% NaCl). All
animals were sacrificed after 90 days and lungs were removed and fixed in
formaldehyde and subsequently processed and stained as described before.
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Experiment 2: Efficacy of gemcitabine
Thirty-three rats were randomized into 5 groups.
At day 0, two groups received 2.0 ´ 106 tumour cells IV for induction of
bilateral lung metastases. Group 1 (n=5) had no treatment and served as the
control group. Group 2 (n=10) received IV treatment with GCB 160mg/kg at
day 7.
At day 0, group 3, 4 and 5 underwent a 10-minute occlusion of the right
pulmonary artery during IV injection of 2.0 ´ 106 tumour cells for induction
of unilateral left pulmonary metastases as described above. Group 3 (n=4)
had no further treatment and served as the control group. On day 7, group 4
(n=7) and 5 (n=7) underwent left ILuP with GCB 320 mg/kg and 480 mg/kg
respectively.
All animals were followed up until death. In order to confirm unilateral or
bilateral micrometastases, a lung biopsy was taken at day 7. Two hemoclips
were placed at the edge of the lung in order to perform a wedge resection.
Biopsies for confirmation of bilateral micrometastases were taken by a
staged thoracotomy with a time interval between the right and left
thoracotomy of two hours.
Results
Experiment 1: Chronic pulmonary toxicity of gemcitabine in rats
Survival rates of experiment 1 were described in a former paper of our
laboratory [15]. Briefly, survival rates for animals treated with left ILuP 20,
40, 80 mg/kg GCB and buffered starch were 100% and 83% for animals
which had left ILuP 160 and 320 mg/kg GCB. Animals treated with IV 40,
80 and 160 mg/kg GCB survived for 100%, 50% and 60% while animals
treated with IV 320 mg/kg GCB died within one week after infusion.
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Histopathological examination showed a significant slight increase of
fibrosis in left lung of animals treated with left ILuP 160 and 320 mg/kg
GCB compared to their untreated right lung (p=0.002). This increase of
fibrosis compared to their right lung was not significant for animals treated
with ILuP 20, 40, 80 mg/kg GCB (p=0.40) and buffered starch (p=0.11). A
non significant tendency in increase of fibrosis in left lung was observed in
rats which had left ILuP 160 and 320 mg/kg GCB compared to ILuP with
20, 40, 80 mg/kg GCB (p=0.06) and buffered starch (p=0.078). Left ILuP
160 and 320 mg/kg GCB resulted in significantly more fibrosis compared to
IV 160 and 320 mg/kg GCB (p=0.002). IV infusion did not result in a
significant increase in fibrosis compared to the control group (p=0.20 and
p=0.24). No significant difference in fibrosis was seen between left and right
lung of rats which underwent iv infusion (table 1-2, fig. 1). Furthermore,
some diffuse alveolar and interstitial infiltrates were observed.
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Figure 1a.
Normal lung
tissue (Masson,
magnification
x400)
Figure 1b.
Mild fibrosis
(Masson,
magnification
x400)
Figure 1c.
Moderate fibrosis
with pleural
fibrosis (Masson,
magnification
x400)
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EFT Normal Lung
Tissue (Figure 1a)
Mild Fibrosis
(Figure 1b)
Moderate
Fibrosis
(Figure 1c)
N N % N % N %
ILuP control 6 4 66.7 2 33.3 0 0
ILuP 40 mg/kg 6 4 66.7 1 16.7 1 16.7
ILuP 80 mg/kg 6 3 50 2 33.3 1 16.7
ILuP 160 mg/kg 6 1 16.7 1 16.7 4 66.7
ILuP 320 mg/kg 6 1 16.7 1 16.7 4 66.7
IV control 6 5 83.3 1 16.7 0 0
IV 40 mg/kg 10 9 90 1 10 0 0
IV 80 mg/kg 10 9 90 1 10 0 0
IV 160 mg/kg 10 10 100 0 0 0 0
IV 320 mg/kg 6 6 100 0 0 0 0
Table 1. Pulmonary fibrosis in the left lung
ILuP: isolated left lung perfusion; IV: intravenous; N: number of rats.
RIGHT Normal Lung
Tissue (Figure 1a)
Mild Fibrosis
(Figure 1b)
Moderate
Fibrosis
(Figure 1c)
N N % N % N %
ILuP control 6 6 100 0 0 0 0
ILuP 40 mg/kg 6 5 83.3 1 16.7 0 0
ILuP 80 mg/kg 6 3 50 3 50 0 0
ILuP 160 mg/kg 6 6 100 0 0 0 0
ILuP 320 mg/kg 6 6 100 0 0 0 0
IV control 6 6 100 0 0 0 0
IV 40 mg/kg 10 9 90 1 10 0 0
IV 80 mg/kg 10 9 90 1 10 0 0
IV 160 mg/kg 10 9 90 1 10 0 0
IV 320 mg/kg 6 6 100 0 0 0 0
Table 2. Pulmonary fibrosis in the right lung
ILuP: isolated left lung perfusion; IV: intravenous; N: number of rats
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Experiment 2: Efficacy of gemcitabine
As described before, rats treated with IV 320 mg/kg died within 1 week
while 83% survived ILuP with the same dose. Therefore 160 mg/kg was
used to determine IV efficacy and 320 and 480 mg/kg were used to evaluate
efficacy in ILuP. The occurrence of pulmonary micrometastases was
confirmed histologically for the unilateral groups as well as for the bilateral
groups. No significant difference (p=0.87) in median survival was seen
between group 1 (28±2 days, bilateral metastases without iv infusion) and 2
(27±2 days, bilateral metastases with 160 mg/kg). Median survival was
significantly longer (p=0.02) in group 4 (38±4 days, unilateral metastases
with ILuP 320 mg/kg) compared to group 3 (28±2 days, unilateral
metastases without ILuP) (table 3). Five animals in group 5 (unilateral
metastases with ILuP 480 mg/kg) died during ILuP due to acute toxicity
while two animals survived for 34 and 36 days in the ILuP 480 mg/kg group.
Group Treatment Median survival
Group 1 (n=5) bilateral controls 28 ± 2 days
Group 2 (n=10) IV GCB 160 mg/kg 27 ± 2 days
Group 3 (n=4) unilateral controls 28 ± 2 days
Group 4 (n=7) ILuP GCB 320 mg/kg 38 ± 4 days (ip=0.01; up=0.02)
Table 3. Survival after IV injection of CC531S adenocarcinoma cells without
(group 1-2) and with concomitant right pulmonary artery occlusion (group
3-4); ILuP: isolated left lung perfusion; IV: intravenous; GCB:
gemcitabine ; i: Group 4 compared to Group 1
u: Group 4 compared to Groups 2 and 3
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Discussion
Pulmonary metastases from colorectal adenocarcinoma are responsible for
56,600 deaths in the United States each year [1]. Despite combination
therapy 5-year survival rate is only 30-40% [2]. Surgical resection only
eradicates manually palpable nodules while microscopic disease remains
unaffected. On the other hand, systemic chemotherapy results in high
systemic toxicity with only low local lung levels. Therefore, a model of ILuP
was developed by Weksler in order to obtain higher local drug
concentrations without systemic toxicity [4]. Many drugs like melphalan,
FUDR, TNF, doxorubicin and cisplatin have been evaluated successfully in
this model in preparation of human studies [7,17,20,21,22-25].
GCB (difluorodeoxycytidine, dFdC) is a relatively new anticancer
nucleoside which is very promising in treatment of non-small cell lung
carcinoma, ovarian carcinoma, soft tissue carcinoma, pancreatic, breast and
colon carcinoma [9-12]. GCB is a pro-drug and must be phosphorylated
intracellularly by deoxycytidine kinase to an active form. Incorporation of
GCB di- and tri-phosphate into the elongating DNA strand makes it unable
for the DNA polymerases to proceed with DNA synthesis [26].
This study investigated survival and pulmonary toxicity after left ILuP with
GCB. Pulmonary toxicity in systemic administration is usually mild and self-
limiting [27]. In literature, some cases of acute respiratory distress syndrome
(ARDS), interstitial pneumonitis and systemic capillary leak syndrome
(SCLS) have been described [14,26,27]. Our study showed some diffuse
interstitial infiltrates in accordance with the case report described by Rosado
[26]. Pulmonary fibrosis in systemic administration has not been reported till
now.
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In this study, all animals treated IV with GCB 320mg/kg died within one
week after infusion while 83% survived after ILuP with 320 mg/kg GCB.
However, histological examination showed a significant slight increase in
fibrosis after ILuP with 160 and 320 mg/kg compared to the untreated right
lung (p=0.002) and compared to IV infusion with the same doses (p=0.002).
A non-significant tendency in increase of fibrosis was seen after ILuP 160
and 320 mg/kg compared to ILuP with the lower doses (p=0.06) and the
ILuP control group (p=0.08). There seems to be a dose dependency in level
of fibrosis. Apparently, IV infusion did not result in increase of fibrosis
compared to the IV control group. Fibrotic changes, septal thickening and
interstitial infiltrates were described earlier for melphalan and cisplatin
[7,20,25]. Further research is necessary to determine the clinical
consequences of pulmonary fibrosis.
Furthermore, efficacy of GCB was evaluated in this study. Systemic
administration of 160 mg/kg GCB did not prolong survival while ILuP 320
mg/kg GCB resulted in significantly longer survival compared to the control
group (p=0.02). Another group was treated with ILuP 480 mg/kg. Five of
seven rats died during ILuP due to acute pulmonary toxicity. In literature,
only two studies reported significantly longer survival after ILuP using 2
mg/kg melphalan (p=0.0002) and 6.4 mg/kg doxorubicin (p<0.0001) using
the unilateral model of pulmonary metastases [15,22].
Our results show that GCB is a promising product for the treatment of
pulmonary metastatic colorectal adenocarcinoma. The unique combination
of metabolic properties and mechanistic characteristics suggests that GCB is
likely to be synergistic if combined with other drugs that damage DNA [28].
Therefore, combination of GCB with melphalan should be tested in order to
lower the doses of GCB and melphalan and to decrease pulmonary toxicity.
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Van Moorsel et al. described synergistic activity after combination therapy
in vitro using GCB and mitomycin C which is an alkylating agent like
melphalan [29]. This effect is possibly based on the property of GCB to
enhance DNA alkylation by mitomycin C.
In conclusion, GCB has proved to be an effective drug against colorectal
CC531S adenocarcinoma in this pulmonary metastatic rat model of ILuP.
Fibrotic septal thickening after 90 days is slight and seems to be dose
dependent. However, pulmonary toxicity does not seem to be more serious
compared to other effective drugs tested in this model.
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Abstract
Introduction: Isolated lung perfusion (ILuP) is an experimental surgical
technique for the treatment of lung metastases. Currently, ILuP with a single
agent does not result in complete remission. Because of their different
mechanisms of cytotoxicity we studied the in vivo efficacy of combinations
of gemcitabine (GCB), cisplatin (CDDP) and melphalan (MN) administered
by ILuP.
Material and methods: In order to induce left pulmonary metastases, sixty-
three rats had intravenous injection of 2.0´ 10E6 viable CC531S colorectal
adenocarcinoma cells with clamping of the right pulmonary artery during ten
minutes. At day 7, except for the control group (n=21), all rats underwent
left ILuP during 25 minutes at a flow rate of 0.5 mL/min using GCB (n=7),
CDDP (n=9), MN (n=7), GCB/CDDP (n=6), GCB/MN (n=6) and
CDDP/MN (n=7). Death due to metastatic disease or sacrifice at day 90 was
the endpoint of the study. Survival analysis was performed by the Kaplan
Meier method and differences in survival assessed by the log rank test.
Statistical significance was defined as p<0.05.
Results: All treated rats lived significantly longer compared to control rats
(p<0.00001) while ILuP GCB/MN was superior compared with all other
groups (p£0.011). ILuP monotherapy with MN resulted in longer survival
compared to GCB (p=0.017) and CDDP (p=0.01). ILuP MN/CDDP
(p=0.029 vs CDDP; p=0.0038 vs MN) and ILuP GCB/MN (p=0.0007 vs
MN; p=0.0004 vs GCB) resulted in important synergistic actions. No
synergistic activity was observed after ILuP GCB/CDDP.
Conclusion: ILuP monotherapy or combination therapy using GCB, CDDP
or MN resulted in significantly longer survival compared to controls. ILuP
monotherapy with MN and combination therapy with MN/GCB gave the
best survival results.
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Introduction
Isolated lung perfusion (ILuP) with chemotherapy is an experimental
surgical technique for the treatment of pulmonary metastases in order to
improve the current mean 5-year survival of approximately 40%. Based on
the finding that cell kill of tumour cells due to chemotherapeutics is
concentration-dependent, ILuP aims to obtain higher local drug levels
without systemic toxicity in order to destroy micrometastases before
resection of manually palpable metastases [1]. Therefore, animal models of
isolated lung perfusion using sarcoma and carcinoma cell lines were set up
to test toxicity, pharmacokinetics and antitumour activity of several drugs
like doxorubicin, TNF-a, melphalan, cisplatin, FUDR and gemcitabine [2-
10]. Former studies in our laboratory showed significantly longer survival in
rats with lung metastases which had ILuP monotherapy using gemcitabine
and melphalan compared to control rats [6,10]. Although significantly longer
survival was achieved using ILuP monotherapy, none of these drugs resulted
in complete remission.
Gemcitabine (GCB) is a deoxycytidine analogue with proven clinical
activity in ovarian, breast, colorectal, pancreas, bladder cancer, small cell
lung cancer (SCLC) and non-small cell lung cancer (NSCLC) [11,12]. After
entering the cell, GCB is phosphorylated and incorporated into the DNA.
Subsequently, one nucleotide has to be added until DNA polymerase is not
capable any more to proceed (“masked chain termination’’). Mainly S-phase
cells proved to be sensitive to GCB. Beside actions on DNA, GCB has some
self-potentiating mechanisms within the cell. Because of its low toxicity
profile and its mechanistic and metabolic properties GCB seems to be a very
interesting drug for combination therapy.
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Cisplatin (CDDP) is a platinum compound and has proven clinical activity
against many of earlier mentioned types of cancer. CDDP does not only
affect the DNA but the mitochondrial RNA, phospholipid membranes and
the cytoskeleton as well. Melphalan (MN) is an alkylating agent and it is not
cell phase specific resulting in DNA-interstrand, or DNA-protein cross-links
causing inhibition of DNA synthesis.
Because of their different mechanisms of cytotoxicity we studied the in vivo
efficacy of combinations of GCB, CDDP and MN for the treatment of
pulmonary metastatic colorectal adenocarcinoma in a rat model of ILuP.
Material and methods
Animals
Male inbred Wag-Rij strain rats (weight, approximately 250g), obtained
from Iffa Credo (Charluff River, Belgium), were used for all experiments.
Animals were treated in accordance with the Animal Welfare Act and the
“Guide for the Care and Use of Laboratory Animals” (NIH Publication 86-
23, revised 1985). The rats were transported in sterile conditions, housed in
suspended mesh wired cages under standard laboratory conditions and ad
libitum fed a standard pellet diet (standard rat chow, Hope Farms, Woerden,
The Netherlands). The experimental protocols were approved by the Ethical
Committee of the University of Antwerp.
Cell line
In this study CC531S adenocarcinoma cell line was used to determine the
sensitivity for the cytotoxic effect of GCB.
CC531S was cultured in RPMI-1640 medium, supplemented with 10% fetal
calf serum (Life Technologies, Merelbeke, Belgium). Cultures were
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maintained in exponential growth in a humidified atmosphere at 37°C under
5% CO2/95% air.
Left Isolated Lung Perfusion
Left ILuP was performed according to the technique described by Wang et
al. [5]. This was modified in our laboratory and full details have been
reported previously by Hendriks et al. [13-15]. Briefly, rats were
anaesthetized with isoflurane in a mixture of nitrous oxide (NO2) and oxygen
(O2). Isoflurane was administered in a concentration of 4% and the NO2:O2
ratio was 3:1. After 5 minutes, rats were intubated with a 16-gauge Insyte-W
catheter by translaryngeal illumination under direct vision and afterwards
ventilated with a volume-controlled ventilator (Harvard Rodent Ventilator,
South Natick, MA) [13]. Once connected to the ventilator, the NO2:O2 ratio
was set to 1:1 (0.5 L/min) and the rate of ventilation was 75 strokes/min with
a tidal volume of 10 mL/kg. Subsequently, the left chest was shaved and
prepared with a 70% alcohol solution followed by a left thoracotomy
between the third and fourth rib. After placing a rib retractor, the left lung
was luxated anteriorly and the hilum was dissected free under microscopic
view (x16 magnification; Carl Zeiss, Belgium). The pulmonary artery and
vein were clamped with curved microvascular clips (Kleinert-Kurz
WK65145). A PE-10 perfusion catheter (Becton Dickinson, Bornem,
Belgium) was introduced into the chest through a 16-G Angiocath, which
was placed through the chest wall. The PE-10 catheter was inserted into the
pulmonary artery and fixed with a 4/0 silk tie. Perfusate was delivered
through this catheter. The effluent was collected at the venous side by a
catheter in proximity of the venotomy. The left thorax was flushed with 2
mL saline every five minutes.
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In all experiments, rats were perfused during 25 minutes followed by a 5-
minute washout with buffered starch using a roller-pump at a rate of 0.5
mL/min. At completion of the perfusion, the arteriotomy was repaired with
10-0 nylon suture (Ethilon, Ethicon, Dilbeek, Belgium). No venotomy repair
was performed but pressure was applied with gauze placed over the lung to
control the bleeding from the venotomy. The thoracotomy incision was
closed in layers after introducing a 16-gauge catheter connected to a 50-mL
syringe into the left chest cavity. When animals recovered, the chest tube
and endotracheal tubes were removed.
Gemcitabine (Difluorodeoxycytidine, Eli Lilly, Brussels, Belgium),
melphalan (Alkeran, 50 mg/vial, Wellcome, Waterloo, Belgium) and
cisplatin (cis-dichlorordiammineplatinum, CDDP, Bristol-Myers, Waterloo,
Belgium) solutions were prepared by reconstituting lyophilized powder in
the supplied diluent and performing appropriate dilutions with buffered
hydroxy-ethyl starch (Haes Steril, BHE) prior to the experiments. The
optimal dose of gemcitabine, cisplatin and melpalan to be administered by
ILuP was determined in former experiments [1,5,16]
Induction of unilateral pulmonary metastases
At day 0, sixty-three rats were infused with 2.0x10E6 viable CC531S
adenocarcinoma cells through the left femoral vein while clamping the right
pulmonary artery during ten minutes for induction of left pulmonary
metastases as described in previous papers [5,10]. Briefly, anaesthesia was
induced as described before. After a right thoracotomy, the rib retractor was
placed in the third intercostal space. After luxating the right upper and
middle lobe posteriorly, the right pulmonary artery was dissected free under
microscopic view (x16 magnification; Carl Zeiss, Belgium). Subsequently, a
longitudinal incision was made along the posterior border of the superior
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caval vein and the right main pulmonary artery was identified. Finally, an
occluding curved microvascular clamp (Kleinert-Kurz WK65145) was
placed over the main pulmonary artery. The rat was repositioned in order to
get access to the left femoral vein for infusion of the tumour cells. The clamp
on the right pulmonary artery was removed after ten minutes. The groin
incision was subsequently closed with a running suture. After full lung
reexpansion, the chest was closed in three layers with 4-0 vicryl and the
animal was allowed to recover from anaesthesia.
Statistical analysis
Survival curves were constructed by the Kaplan Meier method and
differences in survival assessed by the Log Rank test using SPSS version
11.0 for Windows (Chicago, Ill). Significance was determined as p<0.05.
Experiment: survival after isolated lung perfusion using
melphalan, gemcitabine and cisplatin (fig. 1)
At day 0, sixty-three rats were infused with 2.0x10E6 viable CC531S
adenocarcinoma cells through the left femoral vein while clamping the right
pulmonary artery during ten minutes for induction of left pulmonary
metastases as described before. At day 7, all rats were randomized into 7
groups. Groups 1 to 3 underwent ILuP with 320 mg/kg GCB (n=7), 3 mg/kg
CDDP (n=9) and 2 mg/kg MN (n=7) respectively. Groups 4 to 6 had ILuP
using 320 mg/kg GCB combined with 3 mg/kg CDDP (n=6), 320 mg/kg
GCB combined with 2 mg/kg MN (n=6) and 3 mg/kg CDDP combined with
2 mg/kg MN (n=7) respectively. Group 7 was the untreated control group
(n=21) (fig.1). The end point of the study was death due to metastatic
disease.
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N Day 0 Day 7 Endpoint
N=7 Left ILuP GCB
N=7 Left ILuP MN
N=9 Left ILuP CDDP
N=6 Left ILuP GCB+MN
N=6 Left ILuP GCB+CDDP
N=7 Left ILuP CDDP+MN
N=21
IV infusion of 2.0x10E6
viable CC531S
adenocarcinoma cells
while clamping the right
pulmonary artery
No treatment
Death due to
metastatic
disease or
sacrifice at
day 90
Figure 1. Experimental setting.
ILuP: isolated lung perfusion; IV : intravenous; GCB: gemcitabine (320
mg/kg); MN: melphalan (2 mg/kg); CDDP: cisplatin (3 mg/kg)
Results
All rats that had ILuP monotherapy or combination therapy lived
significantly longer compared to untreated control animals (p<0.00001) .
Rats that underwent ILuP with MN had significantly longer survival
compared to ILuP with GCB (p=0.0017) and to ILuP with CDDP (p=0.01).
No significant difference was observed in survival between ILuP using GCB
or CDDP (p=0.096). Combination ILuP using GCB/MN resulted in
significantly longer survival compared to all other groups (p£0.011). 67% Of
the rats in the ILuP GCB/MN group survived the follow-up period of 90
days while no rats did in other groups. Combination ILuP using MN/CDDP
resulted in significantly longer survival compared with CDDP (p=0.029) and
with MN (p=0.0038).
Chapter 7
125
survival after ILuP
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Figure 2. Mean survival after Isolated Lung Perfusion using single-agent
therapy and combinations of gemcitabine, melphalan and cisplatin.
ILuP GCB CDDP MN GCB/MN GCB/CDDP CDDP/MN No ILuP
N 7 9 7 6 6 7 21
Mean ± SE (days) 38±1 42±3 44±2 79±7 47±2 56±4 28±1
% survival at day 90 0 0 0 67 0 0 0
P-value vs GCB/MN 0.0004 0.0015 0.0007 0.0016 0.011 <0.00001
Table 1. Survival after ILuP mono or combination therapy (SE: standard
error).
Significantly longer survival was seen after combination ILuP using
GCB/CDDP compared with GCB (p=0.0004) and with MN/CDDP
(p=0.028) while no longer survival was observed compared with CDDP
(p=0.36) (figure 2 and table 1).
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Discussion
In order to improve efficacy of isolated lung perfusion (ILuP) for the
treatment of pulmonary metastases, this study investigated synergistic
actions in tumour cytotoxicity using combinations of gemcitabine (GCB),
cisplatin (CDDP) and melphalan (MN). Survival was determined in a rat
model of pulmonary metastatic colorectal adenocarcinoma using CC531S
adenocarcinoma cells. One week after induction of micrometastases in the
left lung, rats were treated with left ILuP and survival until death due to
metastatic disease was compared with untreated control animals.
ILuP is based on the concentration dependency of cytotoxicity of
chemotherapeutic drugs [1]. Therefore, it aims to deliver higher local drug
levels without systemic leakage compared to intravenous treatment in order
to destroy micrometastases and therefore to prevent recurrences. Animal
studies investigating efficacy of ILuP with several drugs like GCB, MN,
FUDR, TNF, doxorubicin and CDDP were promising but did not result in
complete remission with exception of a single rat [2-10]. However, MN was
the most successful drug tested which resulted in a currently ongoing phase I
trial at the University Hospital Antwerp (Antwerp, Belgium) and the
Antonius Hospital (Nieuwegein, the Netherlands) including 16 patients until
June 2003. Furthermore, four phase I trials have been described discussing
doxorubicin, CDDP and TNF [17-20]. Although it was not the aim of these
studies to evaluate efficacy, results were disappointing. An explanation for
these disappointing results could be the invasive nature of this technique
which limits repetitive treatment. Furthermore, all phase I trials evaluated
single-agent therapy while the currently used intravenous treatment for
cancer often applies combination chemotherapy [21].
Because of their different mechanisms of cytotoxicity, synergistic actions
were investigated in the present study using combinations of GCB, MN and
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CDDP. ILuP with each single drug resulted in significantly longer survival
compared to control animals. Cells were stored under standardized
circumstances. Survival of rats treated with GCB were comparable with
former results in our laboratory while CDDP was only tested in sarcoma
cells before [9,10].
Theoretically, GCB and CDDP interact at different levels from cellular
uptake until incorporation into the DNA. GCB might interact with either the
uptake of CDDP or the binding of CDDP to DNA. Otherwise, CDDP could
interact with the cellular uptake, the phosphorylation or incorporation into
DNA [22]. Van Moorsel et al. concluded from in vitro studies that the effect
of GCB on CDDP accumulation or DNA platination might be important
factors in this synergistic action. The best synergistic effect was observed
when GCB was administered four hours before CDDP [23]. This finding
explains that only a non-significant synergistic tendency was found in the
present study in which both drugs were delivered simultaneously (p=0.0004
compared with GCB; p=0.36 compared with CDDP). However, repetitive
administration might be possible in less invasive models as blood flow
occlusion without clamping of the pulmonary veins or by intravenous pre-
treatment with GCB (15).
The mechanism of cytotoxicity of GCB is totally different from MN. MN
can be activated to an alkylating agent resulting in DNA crosslinks while
GCB is incorporated into the DNA after phosphorylation to GCB
triphosphate [24]. Van Moorsel et al. suggested that GCB might enhance the
DNA alkylation by mitomycin C which is also an alkalyting agent while
mitomycin C did not have any effect on GCB triphosphate DNA
incorporation [24]. In contrast to these small synergistic actions between
GCB and alkalyting agents, the present study shows an important synergistic
action using GCB combined to MN (p=0.0007 compared with MN ;
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p=0.0004 compared with GCB). However, one rat was in complete
histologic remission at sacrifice.
Finally, ILuP with MN and CDDP was evaluated resulting in significant
synergistic action (p=0.029 compared with CDDP; p= 0.0038 compared with
MN).
In conclusion, ILuP monotherapy with GCB, CDDP or MN enhances
survival of rats with pulmonary metastases while MN is the strongest agent
evaluated. Synergistic actions in survival were observed after ILuP with
GCB/MN and MN/CDDP while GCB/MN is the strongest combination
tested. Therefore, we advocate a phase I trial with ILuP using GCB
combined with MN for the treatment of lung metastases.
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General discussion
Cancer remains the second cause of death with almost 550 000 deaths
expected for the USA in 2002 [1]. Currently, 40-50% of all cases of
malignancy is cured [2]. The non-cured group mostly suffers from
metastases. At the moment of diagnosis of the primary tumour, metastases
which are too small to be detected, so called micrometastases, may already
be present. Furthermore, widespread metastatic disease may be symptomless
at an early stage.
With exception of the lymph nodes, the lungs are the most common site of
metastatic involvement for all invasive cancer types. The most obvious
reason is the filtering of circulating tumour cells by the pulmonary capillary
bed. The precise incidence of pulmonary metastases is unknown, but has
been estimated to occur in up to 50% of patients with non-pulmonary
malignancy [2].
The cumulative incidence and prevalence of pulmonary metastases vary
widely according to tumour type and disease-free time interval. Some
tumour types preferentially metastasise to the lungs, such as sarcomas, germ
cell tumours and some paediatric malignancies. Gastrointestinal tumours will
first metastasise to the liver and from there to the lungs. The high incidence
of pulmonary metastases in autopsy studies may overestimate both the true
incidence of initial lung involvement and its clinical significance.
Current treatment of pulmonary metastases consists of surgical resection and
adjuvant chemotherapy resulting in a 5-year survival of 30-40% [3]. Surgical
treatment only resects manually palpable metastases while micrometastases
remain untouched and finally result in recurrences. Systemic chemotherapy
fails because of genetic drug resistance and the inability to achieve sufficient
drug levels in lung and tumour tissue. So, novel techniques should be
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developed in order to improve prognosis. It was Creech in 1959 who first
reported a model of isolated lung perfusion to achieve high local drug levels
without apparent systemic toxicity [4]. Later on, this model was transposed
to the rat by Weksler and modified by Wang and subsequently by Hendriks
[5-7]. In preparation of clinical trials several drugs were tested like
melphalan, FUDR, TNF, doxorubicin and cisplatin [8-15].
Part of this PhD thesis aimed to investigate the application of gemcitabine
(GCB) for the treatment of pulmonary metastatic colorectal adenocarcinoma
in a rat model of isolated lung perfusion (ILuP). Clinical activity of single-
agent treatment with gemcitabine is currently described for ovarian, breast,
colorectal, breast, pancreas and non-small cell lung cancer [16-17].
Concluding from our studies, GCB is an effective drug against colon
adenocarcinoma in vitro showing time- and concentration-dependent cell kill
[18,19]. Basically, concentration-dependent cell kill is the main argument for
application of isolated lung perfusion resulting in significantly higher drug
levels compared to the currently used intravenous (IV) chemotherapeutic
treatment. However, studying an equilibrium between achieving high local
drug levels and avoiding major pulmonary toxicity on the other hand, is
essential for optimal efficacy. Furthermore, isolated lung perfusion with
GCB resulted in significantly higher lung levels and less acute toxicity when
compared to IV treatment. The maximally tolerated dose after ILuP was 320
mg/kg and 160 mg/kg after IV infusion [18]. Therefore, the pharmacokinetic
benefit of ILuP has been confirmed and is in agreement with results obtained
before in rat studies using melphalan and doxorubicin [8,11,13].
Pulmonary toxicity in systemic administration of GCB is usually mild and
self-limiting [20]. In literature, some cases of acute respiratory distress
syndrome (ARDS), interstitial pneumonitis and systemic capillary leak
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syndrome (SCLS) have been described [20-22]. Our chronic
histopathological studies of rat lungs which underwent ILuP with GCB
showed mild and dose-dependent pulmonary fibrosis of the interstitial and
pleural tissue while obviously no fibrosis was observed in the IV treated and
control rats [23]. Pulmonary fibrosis in ILuP or after systemic administration
has not been reported till now. Furthermore, some diffuse interstitial
infiltrates were observed which are in accordance with the case report
described by Rosado [22]. Further investigations studying functional
pulmonary capacity are planned to determine possible significant side-
effects.
Efficacy of GCB was determined using the unilateral model of pulmonary
(micro)metastases. After induction of unilateral micrometastases at day 0,
rats were treated after one week with ILuP using the MTD of 320 mg/kg of
GCB. This resulted in significantly longer survival compared to untreated
control animals which were not treated. In literature, only two studies
reported significantly longer survival after ILuP with 2 mg/kg melphalan
(p=0.0002) and 6.4 mg/kg doxorubicin (p<0.0001) using the unilateral
model of pulmonary metastases [9,12].
However, even better results were described in rats treated with melphalan
(84 days survival after inducing micrometastases and ILuP with melphalan
versus 39 days after ILuP with GCB) [12,23].
Although no animal models or ex vivo models can exactly define human
tolerance to any drug, four clinical phase I trials have been performed using
tumour necrosis factor, platinum and doxorubicin respectively [24-27].
Except for one study by Ratto et al., all patients had inoperable pulmonary
metastatic disease and perfusions were performed in the antegrade way. A
recent study supported the antegrade way of perfusion by showing that a
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significant portion of both pulmonary and metastatic tumour vasculature is
fed by the pulmonary arterial circulation [28]. All rat studies selected
antegrade single-pass perfusion for technical reasons and because this
method facilitates drug kinetic studies by ensuring a constant drug
concentration in the perfusate. Technically seen, it is very demanding to
cannulate the pulmonary veins of the rat and even more difficult to restore
the venotomies after perfusion in case of survival experiments. However a
recirculating perfusion system was preferred for clinical trials because it
minimizes the amount of perfusate and drug needed, vascular isolation
becomes more complete and greater flexibility is obtained in regulation of
the perfusion environment. In contrast to the single-pass perfusion technique,
the drug was added as a bolus into the perfusion circuit but due to the
continuous uptake of the drug into the lung, the concentration in the
perfusate decreases in function of time. The fact that drug concentration was
crucial in the rat experiments for the final lung concentration might explain
the large variations in perfusate and lung levels of doxorubicin between
patients receiving the same amount of drug [25]. It also shows the difficulty
of calculating the amount of drug to give each patient. In contrast with
isolated limb perfusion, where doses are calculated by the amount of water
displaced by the limb, no such value is available for lung perfusion studies
[29]. However, as mentioned before, previous animal studies in our
laboratory did not show significant differences in final lung and tissue
melphalan levels between single-pass perfusion and reperfusion [30]. These
findings will simplify isolated lung perfusion with melphalan because
melphalan can be injected as a bolus into the circuit, after stabilization of the
main values, such as temperature, flow, and leakage.
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Based on promising experimental results from our laboratory, a phase I trial
has been started at the University Hospital Antwerp (Antwerp, Belgium) in
cooperation with the St. Antonius Hospital (Nieuwegein, the Netherlands).
Increasing doses of melphalan are administered using ILuP in patients
undergoing resection of lung metastases which are melphalan sensitive.
Until June 2003, 16 patients have been treated in this trial without major
morbidity or mortality. Comparison of results of these clinical trials with the
currently used intravenous treatment is difficult as lung and tumour levels
during intravenous chemotherapeutic treatment are not available.
Furthermore, the impact of flow, retrograde perfusion, ventilation and
sequential perfusion remain unclear.
Although efficacy was not the primary aim of the four described clinical
phase I trials which studied doxorubicin, cisplatin and tumour necrosis factor
in ILuP, survival results were disappointing [24-27]. This can be explained
by the invasive nature of this technique which limits repetitive treatment and
the fact that in most studies ILuP was applied in patients with irresectable
lung metastases. Moreover, all clinical trials evaluated single-agent therapy
while the currently used intravenous treatment for cancer often applies
combination chemotherapy [31].
Before the lungs are involved, colorectal cancer preferentially metastasises
to the liver. Beside surgery and systemic chemotherapy for the treatment of
liver metastases, new experimental techniques are under investigation [32].
In order to improve the current 5-year survival of liver metastases, Savier et
al. recently described a feasibility study of percutaneous isolated hepatic
perfusion (IHP) with melphalan in humans; three courses were given with
time intervals of three and six weeks [33]. During the therapy period, an
implantable device connected to a silicone catheter remained in situ. The
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device was implanted subcutaneously while the catheter was inserted into
the gastroduodenal artery. For each course a double-balloon catheter was put
into the caval vein and a single-balloon catheter into the portal vein for
isolation of the liver circulation. Further studies are necessary to investigate
the clinical impact of repetitive percutaneous treatment on survival of liver
metastases. However, double-balloon techniques are very hard to apply in
the pulmonary circulation because of the complicated anatomic access of the
pulmonary veins. We hypothesized that repetitive, less invasive treatment of
pulmonary metastases can only be achieved by selective pulmonary artery
perfusion during blood flow occlusion without control of the pulmonary
veins.
Therefore, we investigated the first-pass effect of gemcitabine during low
flow pulmonary artery perfusion (0.2 ml/min) using blood flow occlusion of
the pulmonary artery without control of the pulmonary veins in preparation
of less invasive methods of selective perfusion of the lung. Low flow
pulmonary artery perfusion with GCB resulted in significantly lower
systemic GCB serum levels and significantly higher lung levels compared to
intravenous infusion [19]. This emphasizes the feasibility of chemotherapy
infusion of gemcitabine by sequential selective catheterisation of the
pulmonary artery using blood flow occlusion without control of the
pulmonary veins.
Because of their different mechanisms of cytotoxicity, synergistic actions
were investigated in the present study using combinations of GCB, MN and
CDDP. ILuP with each single drug resulted in significantly longer survival
compared to control animals. Survival of rats treated with GCB were
comparable with former results in our laboratory while CDDP was only
tested in sarcoma cells before [15,23].
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Theoretically, GCB and CDDP interact at different levels from cellular
uptake until incorporation into the DNA. GCB might interact with either the
uptake of CDDP or the binding of CDDP to DNA. Otherwise, CDDP could
interact with the cellular uptake, the phosphorylation or incorporation into
DNA [35]. Van Moorsel et al. concluded from in vitro studies that the effect
of GCB on CDDP accumulation or DNA platination might be important
factors in this synergistic action. The best synergistic effect was observed
when GCB was administered four hours before CDDP [36]. This finding
explains that only a non significant synergistic tendency was found in the
present study in which both drugs were delivered simultaneously (p=0.0004
compared with GCB; p=0.36 compared with CDDP). However, repetitive
administration might be possible in less invasive models as blood flow
occlusion without clamping of the pulmonary veins or by intravenous
pretreatment with GCB (19).
The mechanism of cytotoxicity of GCB is totally different from MN. MN
can be activated to an alkylating agent resulting in DNA crosslinks while
GCB is incorporated into the DNA after phosphorylation to GCB
triphosphate [37]. Van Moorsel et al. suggested that GCB might enhance the
DNA alkylation by mitomycin C which is also an alkalyting agent while
mitomycin C did not have any effect on GCB triphosphate DNA
incorporation [37]. In contrast to these small synergistic actions between
GCB and alkalyting agents, the present study shows a important synergistic
action using GCB combined to melphalan (p=0.0007 compared with MN,
p=0.0004 compared with GCB). However, one rat was in complete
histologic remission at sacrifice.
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Finally, ILuP with MN and CDDP was evaluated resulting in significant
synergistic action (p=0.029 compared with CDDP; p= 0.0038 compared with
MN).
Pulmonary ischemia/reperfusion (IR) injury as a result of ILuP, lung emboli,
cardiac surgery, shock or transplantation was recently investigated in our
laboratory by differentiating cellular infiltrates and quantifying lung oedema,
apoptosis and necrosis after one hour of warm ischemia followed by 30
minutes, 1, 2, 3 and 4 hours of reperfusion [38]. ILuP was applied as a flush
procedure in this model. Currently, the role of the neutrophil and
macrophage in occurrence of pulmonary IR injury is quite controversial
while the role of the T-cell is even unknown [39-43]. An important increase
in number of neutrophils was observed after 0.5-4 hours of reperfusion and
after reperfusion and flushing as well which might be an indication for
adhesion and activation of these cells. Macrophages doubled in lung tissue
after IR while a biphasic response was observed for neutrophils. This is the
first study that showed a possible involvement (a four times increase) of T-
cells in lung tissue after 1 hour of warm ischemia and 30 minutes of
reperfusion. Furthermore, apoptosis in total absence of necrosis was
observed together with important alveolar oedema [38]. Further studies are
planned to investigate if this inflammatory response is reversible and antigen
specific .
In conclusion, isolated lung perfusion with gemcitabine for the treatment of
pulmonary metastases results in significantly higher lung levels without
systemic toxicity and significantly longer survival compared to systemic
treatment. Synergistic actions have been observed with GCB in combination
with cisplatin and melphalan even resulting in complete remission.
Furthermore, an important first-pass effect has been shown during selective
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pulmonary artery perfusion without clamping the pulmonary veins. Finally,
the reperfusion technique will simplify isolated lung perfusion with
melphalan because melphalan can be injected as a bolus into the circuit, after
stabilization of the main values, such as temperature, flow, and leakage.
Future research
Feasibility of less invasive models of isolated lung perfusion for the
treatment of pulmonary microscopic and macroscopic metastatic disease has
to be investigated. It should be emphasized that less invasive models will
offer the possibility of repetitive application.
After validation of the current results obtained from animal studies, new
drugs and combination of drugs have to be evaluated.
Alternatives to isolated lung perfusion or chemoembolization should be
explored further. Pharmacokinetics of drugs or non-toxic prodrugs that have
proved to be effective in animal models should be investigated in ex-vivo
models.
Based on experimental animal results, clinical phase I, II and eventually
phase III trials have to be designed. Specific attention should be paid to the
optimal dose or concentration administered to the patient in order to obtain a
constant drug level in the lung and tumour tissue. Methods to increase drug
uptake in metastatic cells should be improved.
Finally, clinical parameters should be determined that predict specific
patterns of metastatic development. By applying significant results of these
trials, isolated lung perfusion will find its way to definite clinical application.
In this way, ultimate prognosis in patients with lung metastases will
hopefully be improved.
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Summary
Isolated lung perfusion (ILuP) is an experimental surgical technique for the
treatment of lung metastases in order to improve the 5-year survival of
approximately 40% after surgical resection. Based on in vitro studies that
show cell kill to be concentration dependent, ILuP as an adjuvant treatment
before surgical resection of manually palpable metastases aims to achieve
significantly higher lung and tumour drug levels without apparent systemic
toxicity in order to destroy micrometastases for prevention of recurrences.
However, repetitive treatment is quite unattractive due to its invasive nature.
This PhD thesis aims to review the literature of this research area (chapter 1
and 2) and to investigate in vitro and in vivo toxicity (chapter 3),
pharmacokinetics (chapter 4) and efficacy (chapter 6) of gemcitabine (GCB)
using a rat model of left ILuP. Furthermore, synergistic actions of GCB were
studied using combinations with melphalan and cisplatin (chapter 7).
Finally, two different techniques of isolated lung perfusion (i.e. single-pass
perfusion versus reperfusion) were compared (chapter 5).
In vitro studies using CC531S adenocarcinoma cells exposed to GCB during
different periods of time showed cytotoxic activity to be concentration- and
time-dependent as well. Concerning (tumour) cell kill as the major target of
chemotherapeutic treatment, these in vitro results imply the importance of
achieving high local drug levels and maintenance of a certain drug level as
well (chapter 3 and 4).
Using a rat model of isolated left lung perfusion, toxicity of GCB in vivo
was investigated in a dose escalating study that showed a maximally
tolerated dose (MTD) of 320 mg/kg after left ILuP and 160 mg/kg after
intravenous infusion. All treated lungs from this rat study were
microscopically investigated after sacrification at 3 months. Only a slight
increase of collagen deposits was observed which was significant in rats
treated with left ILuP 160 and 320 mg/kg while no fibrosis was seen in the
intravenously treated rats (chapter 3 and 6).
The unilateral pulmonary metastatic model was used in order to study in
vivo anti-tumour efficacy of left ILuP with GCB. After induction of
micrometastases in the left lung, left ILuP with GCB resulted in a
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significantly longer survival compared to control rats which were not treated
(chapter 6).
GCB seems to be a very interesting drug for combination therapy because of
its low toxicity profile and mechanistic and metabolic properties. Because of
their different mechanisms of cytotoxicity, we studied the in vivo efficacy of
combinations of gemcitabine, cisplatin and melphalan for the treatment of
pulmonary metastatic colorectal adenocarcinoma in our rat model of isolated
lung perfusion. All single drugs and combinations resulted in a significant
elongation of survival compared to controls. However, ILuP with melphalan
and melphalan combined with gemcitabine gave the best survival results
(chapter 7).
In preparation of less invasive techniques of ILuP, a rat model was
developed to obtain selective pulmonary artery perfusion during blood flow
occlusion without clamping the pulmonary veins. An important first-pass
effect of GCB in the lung was observed resulting in significantly lower
systemic GCB serum levels compared to GCB serum levels after intravenous
infusion of a lower dose (chapter 4).
Finally, in preparation of a clinical trial, two different techniques of ILuP
were compared using melphalan. The single-pass (SP) perfusion technique is
used in all rat studies and implies delivery of a constant concentration of the
drug to the lung while the reperfusion (RP) technique is currently used in an
ongoing clinical phase I trial in the University Hospital Antwerp (Antwerp,
Belgium) and the St. Antonius Hospital (Nieuwegein, the Netherlands)
which implies a delivery of a decreasing concentration of the drug used due
to the uptake into the lung. No significant differences in final lung and
tumour levels were observed between SP and RP if saturation occurs. These
findings will simplify isolated lung perfusion with melphalan because
melphalan can be injected as a bolus into the circuit, after stabilization of the
main values, such as temperature, flow, and leakage (chapter 5).
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Samenvatting
Geïsoleerde Longperfusie (ILuP) is een experimentele chirurgische
behandeling voor de behandeling van longmetastasen om de huidige 5-
jaarsoverleving van ongeveer 40% na chirurgische resectie te verbeteren. In
vitro studies toonden aan dat celdood bij blootstelling aan een
chemotherapeuticum concentratieafhankelijk is. Als een adjuvante
behandeling voorafgaand aan chirurgische resectie van manueel palpabele
metastasen, heeft ILuP als doelstelling om significant hogere long- en
tumorconcentraties te bereiken zonder dat systemische toxiciteit optreedt.
Het is de bedoeling om micrometastasen te vernietigen ter voorkoming van
recidieven. Herhaalde behandeling is technisch bijzonder moeilijk omwille
van het invasieve aspect van de behandeling.
Dit proefschrift heeft als doelstelling om een overzicht te geven van de
literatuur op het gebied van ILuP (hoofdstuk 1 en 2) als behandeling van
longmetastasen. Verder worden in vitro en in vivo toxiciteit (hoofdstuk 3),
farmacokinetiek (hoofdstuk 4) en efficaciteit (hoofdstuk 6) van gemcitabine
(GCB) onderzocht waarbij gebruik wordt gemaakt van een rattenmodel van
ILuP. Bovendien wordt synergistische activiteit onderzocht van GCB in
combinatie met cisplatinum en melphalan (hoofdstuk 7). Uiteindelijk worden
twee verschillende technieken (namelijk de single-pass perfusietechniek
versus de reperfusietechniek) vergeleken (hoofdstuk 5).
In vitro studies hebben laten zien dat cytotoxiciteit zowel concentratie- als
tijdsafhankelijk is. Hierbij werd gebruik gemaakt van de CC531S
adenocarcinomacellijn die werd blootgesteld aan GCB in functie van de tijd.
Het bereiken van celdood is de belangrijkste doelstelling van een
chemotherapeutische behandeling. Daarom impliceren deze in vitro
resultaten het belang van het behalen van een hoge lokale concentratie van
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een chemotherapeuticum maar vooral ook van het handhaven van deze
concentratie (hoofdstuk 3 en 4).
In vivo toxiciteit van GCB werd onderzocht met behulp van een rattenmodel
van ILuP. Hierbij werd een opbouwend dosisschema gebruikt dat een
maximaal tolereerbare dosis (MTD) liet zien van 320 mg/kg voor
behandeling met ILuP en 160 mg/kg na intraveneuze inspuiting. Na drie
maanden werden alle ratten opgeofferd en werden de longen microscopisch
onderzocht. Slechts een lichte toename van collageendeposities werd gezien
die significant was voor de groepen behandeld met ILuP 160 en 320 mg/kg.
In de intraveneus behandelde groepen werd echter geen fibrose aangetroffen
(hoofdstuk 3 en 6).
Een unilateraal model van pulmonaal gemetastaseerd adenocarcinoma werd
gebruikt voor het bepalen van in vivo anti-tumor activiteit van ILuP van de
linker long met GCB. In het dit model worden micrometastasen geïnduceerd
in de linker long. Een significante verlenging van overleving werd gezien na
ILuP met GCB in vergelijking met controledieren die niet werden behandeld
(hoofdstuk 6).
GCB is een erg interessant product voor combinatietherapie omwille van het
lage toxiciteitsprofiel en de mechanistische en metabole eigenschappen. De
in vivo efficaciteit van GCB werd bestudeerd in combinatie met melphalan
en cisplatin omwille van hun verschillende mechanismen van cytotoxiciteit.
Alle producten die als monotherapie werden gebruikt evenals de
verschillende combinaties resulteerden in een significante verlenging van
overleving in vergelijking met controle dieren. Melphalan monotherapie en
melphalan/gemcitabine combinatietherapie gaven echter de beste
overlevingsresultaten (hoofdstuk 7).
ln voorbereiding op minder invasieve technieken van ILuP werd een
rattenmodel ontwikkeld waarbij de pulmonaalarterie selectief werd
geperfundeerd met gelijktijdige bloedflowocclusie aldaar, terwijl de
pulmonaalvenen niet geoccludeerd werden. Een belangrijk first-pass effect
van GCB ter hoogte van de long werd waargenomen dat resulteerde in
significant hogere longconcentraties en significant lagere serumconcentraties
in vergelijking met intraveneuze inspuiting van een lagere dosis GCB
(hoofdstuk 4).
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Ten slotte werden twee verschillende technieken van ILuP met melphalan
vergeleken in voorbereiding van een fase I studie. De single-pass
perfusietechniek (SP) wordt gebruikt in de rattenmodellen en impliceert het
afgeven van een constante concentratie van het product terwijl de
reperfusietechniek momenteel gebruikt wordt in een fase I studie in het
Universitair Ziekenhuis Antwerpen (Antwerpen, België) en het Sint
Antonius Ziekenhuis (Nieuwegein, Nederland). Reperfusie leidt tot het
afgeven van een dalende concentratie van het product als gevolg van de
opname door het longweefsel. Geen significante verschillen werden gemeten
tussen SP en RP in long- en tumorweefsel als verzadiging optreedt. Deze
bevindingen vereenvoudigen ILuP met melphalan, omdat melphalan als een
bolus kan worden toegevoegd aan het circuit na stabilisatie van de
belangrijkste variabelen zoals temperatuur, flow en systemische lekkage
(hoofdstuk 5).
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